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A B S T R A C T
Background
An earlier Cochrane review of dietary advice identified insufficient evidence to assess effects of reduced salt intake on mortality or
cardiovascular events.
Objectives
1. To assess the long term effects of interventions aimed at reducing dietary salt on mortality and cardiovascular morbidity.
2. To investigate whether blood pressure reduction is an explanatory factor in any effect of such dietary interventions on mortality and
cardiovascular outcomes.
Search strategy
The Cochrane Library (CENTRAL, Health Technology Assessment (HTA) and Database of Abstracts of Reviews of Effect (DARE)),
MEDLINE, EMBASE, CINAHL and PsycInfo were searched through to October 2008. References of included studies and reviews
were also checked. No language restrictions were applied.
Selection criteria
Trials fulfilled the following criteria: (1) randomised with follow up of at least six-months, (2) intervention was reduced dietary salt
(restricted salt dietary intervention or advice to reduce salt intake), (3) adults, (4) mortality or cardiovascular morbidity data was
available. Two reviewers independently assessed whether studies met these criteria.
Data collection and analysis
Data extraction and study validity were compiled by a single reviewer, and checked by a second. Authors were contacted where possible
to obtain missing information. Events were extracted and relative risks (RRs) and 95% CIs calculated.
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Main results
Seven studies (including 6,489 participants) met the inclusion criteria - three in normotensives (n=3518), two in hypertensives (n=
758), one in a mixed population of normo- and hypertensives (n=1981) and one in heart failure (n=232) with end of trial follow-
up of seven to 36 months and longest observational follow up (after trial end) to 12.7 yrs. Relative risks for all cause mortality in
normotensives (end of trial RR 0.67, 95% CI: 0.40 to 1.12, 60 deaths; longest follow up RR 0.90, 95% CI: 0.58 to 1.40, 79 deaths)
and hypertensives (end of trial RR 0.97, 95% CI: 0.83 to 1.13, 513 deaths; longest follow up RR 0.96, 95% CI; 0.83 to 1.11, 565
deaths) showed strong evidence of any effect of salt reduction. Cardiovascular morbidity in people with normal blood pressure (longest
follow-up RR 0.71, 95% CI: 0.42 to 1.20, 200 events) or raised blood pressure at baseline (end of trial RR 0.84, 95% CI: 0.57 to 1.23,
93 events) also showed no strong evidence of benefit. Salt restriction increased the risk of all-cause death in those with congestive heart
failure (end of trial relative risk: 2.59, 95% 1.04 to 6.44, 21 deaths). We found no information on participants health-related quality
of life.
Authors’ conclusions
Despite collating more event data than previous systematic reviews of randomised controlled trials (665 deaths in some 6,250 par-
ticipants), there is still insufficient power to exclude clinically important effects of reduced dietary salt on mortality or cardiovascular
morbidity in normotensive or hypertensive populations. Further RCT evidence is needed to confirm whether restriction of sodium
is harmful for people with heart failure. Our estimates of benefits from dietary salt restriction are consistent with the predicted small
effects on clinical events attributable to the small blood pressure reduction achieved.
P L A I N L A N G U A G E S U M M A R Y
Cutting down on the amount of salt has no clear benefits in terms of likelihood of dying or experiencing cardiovascular disease
Cardiovascular disease includes heart attacks, strokes, and the need for heart surgery and is a major cause of premature death and
disability. This review set out to assess whether advice to cut down on salt in foods on altered our risk of death or cardiovascular disease.
Intensive support and encouragement to reduce salt intake did lead to a reduction in salt eaten and a small reduction in blood pressure
after more than six months. There was not enough information to understand the effect of these changes in salt intake on deaths or
cardiovascular disease. Further research in needed to confirm our finding that dietary advice to reduce salt may increase deaths in people
with heart failure.
B A C K G R O U N D
In 2002 it was estimated that nearly 17 million deaths globally
per year result from cardiovascular disease (CVD) (Mackay 2004).
Data on morbidity is more difficult to collect because there are
so many different measures of cardiovascular morbidity. However,
in 2002 it was estimated that over 34 million disability adjusted
life years (DALYs) are lost each year to CVD in Europe (Allender
2008).
The current public health recommendations in most developed
countries are to reduce salt intake by about half, i.e. from approx-
imately 10 to 5 g/day (He 2010; SACN 2003; Whelton 2002 ).
Data from observational studies have indicated that a high dietary
intake of salt is an important risk factor for cardiovascular disease
(He 2002, He 2010). This was confirmed by a recently published
systematic review and meta-analysis of 13 prospective studies in-
cluding 177,000 participants. A high salt intake was associated
with a greater risk of stroke (relative risk, 1.23, 95% CI: 1.06 to
1.43) (Starzzullo 2009). However, there was no association be-
tween salt intake and all cardiovascular events, and total mortality
was not reported. Furthermore, the interpretation of this obser-
vational evidence base is complicated by the heterogeneity in esti-
mating sodium intake (diet or urinary salt excretion), types of par-
ticipants (healthy, hypertensive, obese and non-obese), different
end points, and definition of outcomes across studies (Alderman
2010).
The relationship of salt intake to blood pressure is the basis for the
belief that restriction in dietary sodium intake will prevent blood
pressure related cardiovascular events (Elliot 1996). A number of
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meta-analyses of randomised controlled trials of salt reduction and
blood pressure have been undertaken (He 2004; Jurgens 2004).
Whilst these analyses consistently report a reduction in the level of
blood pressure with reduced salt intake, the level of blood pressure
reduction achieved is less impressive in the longer term. The 2004
Cochrane review of dietary salt restriction intervention studies of
at least six months duration, found that intensive support and
encouragement to reduce salt intake lowered blood pressure at 13
to 60 months but only by a small amount (systolic by 1.1 mmHg,
95% CI: 1.8 to 0.4, diastolic by 0.6 mmHg, 95% CI: 1.5 to -0.3)
(Hooper 2004). The reduction in blood pressure appeared larger
for people with higher blood pressure. A decrease in blood pressure
is only important if it results in a decrease in cardiovascular events
and deaths. Sustained reductions in mean blood pressure of 2-
3 mmHg are necessary for important population reductions in
cardiovascular events (Elliot 1991).
Whilst the Cochrane review also sought to assess the impact of di-
etary salt restriction on mortality and cardiovascular events, across
the included 11 RCTs there were only 17 deaths spread evenly
across groups and 46 cardiovascular events in the controls com-
pared with 36 in low sodium diet groups. This extremely low
number of events substantially limited the ability of this review to
detect small to moderate reductions in the risk of cardiovascular
events.
Given that the effect of interventions to reduce dietary salt on
blood pressure is well established, the primary focus of this review
is to confirm whether such changes in diet are associated with
improvements in mortality and cardiovascular events.
O B J E C T I V E S
1. To assess the long term effects of interventions aimed at reducing
dietary salt on mortality and cardiovascular morbidity.
2. To investigate whether a reduction in blood pressure is an
explanatory factor in the effect of such dietary interventions on
mortality and cardiovascular outcomes.
Interventions to reduce dietary salt were compared with usual,
control or placebo diets, or no intervention.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs; individual or cluster level)
with follow up of at least six months.
Types of participants
Studies of adults (18 years or older), irrespective of gender or
ethnicity. Studies of children or pregnant women were excluded.
Types of interventions
The desired intervention was reduced dietary salt and could in-
clude studies that involved participants receiving a dietary inter-
vention that restricted salt or studies where the intervention was
advice to reduce salt intake. The comparison group could include
usual, control or placebo diet, or no intervention.
Types of outcome measures
Primary outcomes
Mortality (overall and cardiovascular), cardiovascular morbid-
ity (including fatal and non-fatal myocardial infarction, stroke,
angina, heart failure, peripheral vascular events, sudden death,
revascularisation [coronary artery bypass surgery or angioplasty
with or without stenting] and cardiovascular related hospital ad-
missions). Primary outcomes were assessed at study end, and also
at the latest trial follow up where participants had been followed
observationally after the end of the original trial.
Secondary outcomes
In studies that reported primary outcomes we also sought the fol-
lowing secondary outcomes: systolic and diastolic blood pressure,
and urinary salt excretion (or other method of estimation of salt
intake) and health related quality of life using a validated outcome
measure (e.g. Short Form 36, McHorney 1993).
Search methods for identification of studies
Electronic searches
Randomised controlled trials were identified by searching the
Cochrane Central Register of Controlled Trials (CENTRAL) in
TheCochrane Library (Issue 4, 2008),MEDLINE (Ovid, 1950 to
29 October 2008), EMBASE (Ovid, 1980 to 30 October 2008),
CINAHL (Ovid, 2001 to 3 November 2008), and PsycINFO
(Ovid, 1806 to October 2008), Health Technology Assessment
(HTA) and Abstracts of Reviews of Effects (DARE) databases were
searched via The Cochrane Library (Issue 4, 2008). Searches con-
ducted in MEDLINE, EMBASE, CINAHL, and PsycINFO in-
cluded a controlled trials filter. Additional filters were applied to
restrict searches to non-animal studies in MEDLINE and EM-
BASE and to exclude certain publication types from the search
results [Medline: case reports/letters, EMBASE: letters/editorials,
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and PsycInfo: editorials/letters]. No language or additional limits
or filters were utilized. See Appendix 1 for details of the search
strategies.
Searching other resources
Reference lists of all eligible trials and relevant systematic reviews
were searched for additional studies.
Data collection and analysis
Selection of studies
The titles and abstracts of studies identified by the search were
independently screened by two reviewers (KA&RST) and clearly
irrelevant studies discarded. In order to be selected, abstracts had
to clearly identify the study design, an appropriate population and
a relevant intervention/exposure, as described above. The full text
reports of all potentially relevant studies were obtained and as-
sessed independently for eligibility, based on the defined inclusion
criteria, by two reviewers (KA & RST). Any disagreement was
resolved by discussion or where agreement could not be reached,
by consultation with an independent third person (LH).
Data extraction and management
Standardised data extraction forms were used. Relevant data re-
garding inclusion criteria (study design, participants, intervention/
exposure, and outcomes), risk of bias (see below) and outcome
data were extracted. Data extraction was carried out by a single
reviewer (KA or RST) and checked by a second reviewer (RST or
KA). Disagreements were resolved by discussion or if necessary by
a third reviewer (LH). We extracted outcomes at the latest follow
up point within the trial, and also at the latest follow up after the
trial where this was available, as we reasoned this would maximise
the number of events reported. All included authors were con-
tacted to clarify any missing outcome data or issues of risk of bias
assessment.
Assessment of risk of bias in included studies
Factors considered included random sequence generation and al-
location concealment, description of drop-outs and withdrawals,
blinding (participants, personnel and outcome assessment) and
selective outcome reporting. In addition evidence was sought that
the groupswere balanced at baseline, that intention to treat analysis
was undertaken and whether the period over which the salt inter-
vention lasted and follow up of outcome were equivalent. The risk
of bias of included studies was assessed by a single reviewer (KA)
and checked by a second reviewer (RST). Disagreements were re-
solved by discussion or if necessary by a third reviewer (LH).
Data synthesis
Data were processed as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009). For mortal-
ity and cardiovascular events, risk ratio and 95% confidence inter-
vals were calculated for each trial. For blood pressure and urinary
sodium excretion, mean group differences and 95% confidence
intervals were calculated using weighted mean difference. Hetero-
geneity amongst included studies was explored qualitatively (by
comparing the characteristics of included studies), and quantita-
tively (using the Chi2 statistic of heterogeneity and I2 statistic).
Results from included studies were combined for each outcome
to give an overall estimate of treatment effect at the latest point
available within the randomised trial, and, as a secondary analy-
sis, at the latest point available (including where participants were
followed after the end of the randomisation period). A fixed-effect
meta-analysis was used except where statistical heterogeneity (Chi
2 P ≤ 0.05 and I2 value ≥ 50%) was identified, in which case
methodological and clinical reasons for heterogeneity were con-
sidered and a random-effects model was used.
Subgroup analysis and investigation of heterogeneity
It was planned to use stratified meta-analysis to explore the differ-
ential effects that occur as a result of: individual advice vs. pop-
ulation level interventions, baseline risk of cardiovascualr disease
(CVD), and salt reduction only interventions vs. multi-compo-
nent dietary interventions that include salt restriction; and meta-
regression to assess the effects of level of salt reduction achieved,
baseline blood pressure (BP) and change in BP on mortality and
CV event outcomes.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Our electronic and reference list searches identified a total of 2,649
titles of which 2,605 were excluded on title and abstract. After
examining the full texts of the remaining 44 papers, seven trials
were included (38 reports) (Chang 2006 [31 mo]; HPT 1989 [36
mo]; Morgan 1978 [7-71 mo]; Paterna 2008 [6.4 mo]; TOHP I
1992 [18 mo]; TOHP II 1997 [36 mo]; TONE 1998 [30 mo]).
The study selection process is summarised in the flow diagram
shown in Figure 1.
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Figure 1. Study flow diagram
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Five studies from an earlier Cochrane review (Hooper 2004) met
the inclusion criteria (TOHP I 1992 [18 mo]; TOHP II 1997 [36
mo]; TONE 1998 [30 mo]; HPT 1989 [36 mo]; Morgan 1978
[7-71 mo]). The other six included studies from Hooper 2004
were excluded as they did not report mortality or cardiovascular
events (Alli 1992; Arroll 1995; Costa 1981;Morgan 1987; Silman
1983; Thaler 1982). Studies that were assessed in full text, but
excluded, are listed in Characteristics of excluded studies section.
Responses to our request for additional details were obtained from
three of the included trial authors i.e. TOHP I and II and TONE.
Included studies
The seven included studies are described in Characteristics of
included studies section. Three trials in people with normotension
(n=3518, HPT 1989 [36 mo]; TOHP I 1992 [18 mo]; TOHP II
1997 [36 mo]), two in people with hypertension (n=758, Morgan
1978 [7-71mo];TONE1998 [30mo]), one in amixedpopulation
of people with normo- and hypertension (n=1981, Chang 2006
[31 mo]) and one in people with heart failure (n=232, Paterna
2008 [6.4 mo]) were included. Post-randomisation follow up var-
ied from up to six to nine months (Morgan 1978 [7-71 mo];
Paterna 2008 [6.4 mo]), to ~three-years (Chang 2006 [31 mo];
HPT 1989 [36 mo]) and 10-15 years (TOHP I 1992 [18 mo];
TOHP II 1997 [36 mo]; TONE 1998 [30 mo]).
The three normotensive trials were in healthy people (predomi-
nantly [>75%] white, male [75%], median age 40) conducted in
the USA. Entry criteria varied between trials, but included those
with diastolic blood pressure from 78 to 89 mmHg, with a narrow
range of means from 83 to 86 mmHg diastolic and 124 to 127
mmHg systolic and the number of participants included ranged
from 392 to 2382.
All three studies (as well as TONE, below) in normotensives aimed
to reduce salt by a comprehensive dietary and behaviour change
programmes led by experienced personnel, including group coun-
selling sessions, regularly over several months, with newsletters
between sessions, self assessment, goal setting, food tasting and
recipes. For example, the HPT study ran ten weekly group
counselling sessions on food selection, food preparation and be-
haviour management skills, followed by semi-monthly and then
bi-monthly meetings throughout the trial (with newsletters in the
months where no meetings occurred). Sessions were run by nutri-
tionists and behavioural scientists and individual counselling was
provided where participants missed sessions or had special needs.
Techniques used in the sessions included group discussions, in-
structions for dietary record keeping, goal setting, individual diet
analysis for each participant, cooking demonstrations, provision
of recipe books and tasting of new foods. The intervention du-
ration ranged from seven months in the TONE study to some
36 months in TOHP II study. Control groups received no active
intervention. Sodium excretion goals were set at less than 70 to
80mmol/24 hours.
The three trials that included hypertensives included one trial in
treated hypertensive participants (TONE 1998 [30 mo]) and two
for participants with untreated hypertension (Chang 2006 [31
mo]; Morgan 1978 [7-71 mo]). Some 40 percent of participants
in the Chang study were defined as hypertensive. Studies were
carried out in Australia, Taiwan and USA and ranged in size from
77 to 1,981 participants. 58 to 100% of participants were male
with median age of 66 yrs and 76% were white in the TONE
study and 100% were Asian in the Chang study (ethnicity was not
reported in Morgan study). At study entry mean diastolic blood
pressure ranged from 71 mmHg (Chang 2006 [31 mo]; TONE
1998 [30 mo] on treatment) to 97 mmHg (Morgan 1978 [7-71
mo], untreated) and systolic blood pressure ranged from approxi-
mately 131mmHg (Chang 2006 [31 mo] untreated; TONE 1998
[30 mo] on treatment) to 162 mmHg (Morgan 1978 [7-71 mo],
untreated).
Interventions in the three studies included:
• a dietary programme by the cook of the kitchen to which
they were assigned (clustered random allocation), to ’high
potassium salt’ containing 49% sodium chloride, 49%
potassium chloride, and 2% other additives or control prepared
diet using ’usual salt’ containing 99.6% sodium chloride and
0.4% other additives (Chang 2006 [31 mo]).
• advice to reduce dietary sodium chloride intake, with advice
repeated at 6 months compared with no dietary intervention in
the control group (Morgan 1978 [7-71 mo]). Anti-hypertensive
medication was stopped two months after randomisation to
intervention or control, but restarted if diastolic blood pressure
rose. After 6 months, four out of 10 men on low sodium diet
were taking anti-hypertensive medication, compared to nine of
the ten controls (relative risk: 0.44, 95% CI: 0.20 to 0.98).
• a four-month ‘intensive’ plus three-month ‘extended’
individual nutrition and behavioural counselling programme (as
above) or no such programme but with invitations to meetings
on unrelated topics in the control group (TONE 1998 [30 mo]).
In the TONE study hypertensive medication withdrawal could
be attempted began at three-months post randomisation. The
primary composite outcome (high blood pressure at any visit,
restarting anti-hypertensive medication or a cardiovascular event)
was less common in the sodium reduction group than control
(relative risk 0.83, 95% CI: 0.75 to 0.92). The proportions of
individuals restarting medication was not separately reported.
Sodium goals varied from <80 mmol/day (TONE 1998 [30 mo])
to 70-100 mmol/day and unspecified (Chang 2006 [31 mo])
sodium intake.
The final study was undertaken in Italy and included a popula-
tion of participants diagnosed with uncompensated heart failure
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(NYHA class III or IV) (Paterna 2008 [6.4 mo]). The majority
of participants were male with a mean age of 73, mean diastolic
blood pressure of 82.5 mmHg and mean systolic blood pressure
of 125.5 mmHg. The intervention group received written stan-
dard diet sheets containing 80mmol of sodium daily prepared by
dietitians and the control group received the same dietary advice
but with the addition of 40mmol of sodium per day. In addition
to either low-sodium or control diet, both groups received a high
dose diuretic (furosemide, 250-500 mg bid).
Risk of bias in included studies
Anumber of studies failed to give sufficient detail to assess their po-
tential risk of bias. Details of generation and concealment of ran-
dom allocation sequence were particularly poorly reported (Figure
2; Figure 3). However, in all cases there was objective evidence
of balance in baseline characteristics of intervention and control
participants. While studies reported loss to follow up and reasons
for loss for follow, only a few undertook a sensitivity or imputation
analysis to assess the impact of these losses, followed up partici-
pants for event outcomes and described reasons for loss to follow
up for other outcomes. In the TONE trial, the authors stated that
data were collected via psychological questionnaires at randomi-
sation and a number of the follow-up visits. However, none of
these data were found in trial reports. Although often not stated,
all studies appeared to undertake an intention to treat analysis in
that groups were analysed according to initial random allocation.
All studies assessed compliance to salt reduction intervention us-
ing diet diaries or monitoring USE. However, in the longer term
follow up of the TOHP I (11.5 yrs), TOHP II (8 yrs) and TONE
(12.7 yrs) trials such compliance data was not reported beyond
the official end of the study. Therefore it was unclear whether in-
tervention groups encouraged to continue their low salt diets, or
return to their pre-trial diet. Similarly, control groups may have
been left to continue with their usual diet or advised to reduce
their salt at the end of the trial.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
Given the heterogeneity in populations, results are presented and
pooled separately for studies of people with normotension, hyper-
tension and heart failure. Outcomes were pooled at end of trial
and at longest follow up point unless otherwise indicated.
Mortality
All cause mortality was reported at the end of the trial in five of
the included studies (HPT 1989; TOHP I 1992; TOHP II 1997;
Chang 2008; Morgan 1978). Trials were homogeneous and there-
fore pooled using a fixed effect model. There was weak evidence of
a reduction in the number of deaths in the reduced salt group rela-
tive to controls for normotensives (fixed effects RR 0.67, 95% CI:
0.40 to 1.12, 60 deaths in total, Chi² p-value=0.96,I² = 0%) and
hypertensive populations (fixed effects RR 0.97, 95% CI: 0.83 to
1.13, 513 deaths, Chi² p-value = 0.98, I² = 0%). Compared to
control there was an increase in deaths with dietary salt reduction
in the single heart failure study (relative risk: 2.59, 95% CI: 1.04
to 6.44, 21 deaths). See Analysis 1.1
A longer observational follow up following the end of the ran-
domised trial period was reported for the TOHP I (11.5 yrs) and
TOHP II (8 yrs) trials (Cook 2007) and we were able to obtain
longer observational unpublished data from the authors from the
TONE study (12.7 yrs). Trials remained homogeneous. At longest
follow up, there was still no strong evidence of a reduction in the
number of deaths in the reduced salt group relative to controls, for
the normotensives (fixed effects RR 0.90, 95% CI: 0.58 to 1.40,
79 deaths in total, Chi² p-value=1.00,I² = 0%) or hypertensive
populations (fixed effects RR 0.96, 95% CI: 0.83 to 1.11, 565
deaths, Chi² p-value = 0.92); I² = 0%). See Analysis 1.2
Cardiovascular mortality was only reported in two studies of hy-
pertensive patients. Both studies only reported trial end data.
Chang reported a lower proportion of cardiovascular deaths in re-
duced salt group (27 died; 1310.0 per 100,000 person years) than
in the control group (66 died; 2,140 per 100,000 person years).
Morgan reported only five cardiovascular deaths, three in the in-
tervention and two in control group. The pooled relative risk
was consistent with a halving of the relative risk of cardiovascular
deaths or a small increase (fixed effects RR 0.69, 95% CI: 0.45 to
1.05, 98 cardiovascular deaths, Chi² p-value = 0.26, I² = 0%). See
Analysis 1.3
Cardiovascular morbidity
Overall cardiovascular morbidity was available for four trials.
There was some evidence of statistical heterogeneity which may
reflect that the definition of CV morbidity varied from trial to
trial, although it broadly consisted of a composite of myocardial
infarction, stroke, coronary artery bypass, PTCA, or death from
a cardiovascular cause. At longer term observational follow up,
TOHP I reported a relative risk reduction of cardiovascular events
of 49% (95% CI: 9% to 71%) with reduced salt although when
pooled with long term observational follow up of TOHP II there
was no strong evidence of benefit in normotensive participants
(random effects relative risk: 0.71, 95% CI: 0.42 to 1.20, 200
events, Chi² p-value = 0.10; I² = 63%). There were no reports of
cardiovascular morbidity during or at the end of the randomised
period for TOHP I or II trials. We found no strong evidence of
benefits of salt reduction in hypertensive individuals (fixed effects
relative risk: 0.84, 95% CI: 0.57 to 1.24, 93 events, Chi² p-value
= 0.53; I² = 0%) at end of trial. See Analysis 1.4
Individual cardiovascular morbidity outcomes were infrequently
reported and at trial end only. Paterna et al reported 39 cardiovas-
cular-related hospital admissions (30 intervention, nine control)
in their study of congestive heart failure patients (Paterna 2008
[6.4 mo]). In TONE, three patients experienced strokes (one in-
tervention, two control); six experienced a myocardial infarction
(two intervention, four control); three developed heart failure (two
intervention, one control) and 26 suffered from angina (nine in-
tervention, 17 control) (TONE 1998 [30 mo]).
Blood pressure
End of trial blood pressure was reported by all studies. There
was evidence of substantial statistical heterogeneity. Systolic blood
pressure was reduced in all intervention arms - normotensives (ran-
dom effects mean difference 1.1 mmHg, 95%CI -0.1 to 2.3, Chi²
p-value = 0.05, I² = 67%), hypertensives (fixed effect mean dif-
ference 4.1 mmHg, 95% CI 2.4 to 5.8, Chi² p-value = 0.64; I² =
0%) and those with heart failure (by 4.0 mmHg, 95% CI 0.7 to
7.3). Diastolic blood pressure was also reduced in normotensives
(fixed effect mean difference 0.8 mmHg, 95% CI 0.2 to 1.4, Chi²
p-value = 0.39); I² = 0%) but not in hypertensives (random effect
mean difference -3.7 mmHg, 95% CI: 0.9 to -8.4, Chi² p-value
= 0.08; I² = 67%) or those with heart failure (mean difference -
2.0 mmHg, 0.70 to -4.80). See Analysis 1.5 and Analysis 1.6.
Urinary sodium excretion
Changes in urinary sodium excretion (USE) at the end of trial
were reported by all studies. There was some evidence of statistical
heterogeneity which may reflect different approaches to the assess-
ment of 24-hr urinary sodium excretion. In the study by Morgan
(Morgan 1978 [7-71 mo]), results were only reported as samples
and therefore contained repeated observations for a number of
patients. As for BP, in a number of studies, the last USE available
was at a time point much preceding the timing of the reported
mortality or CV events (BP follow up time: Morgan - six mo;
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TONE - 30 mo, TOHP I - 18 mo, TOHP II - 36 mo). Urinary
24-hour USE was reduced by a similar amount across the three
study subgroups - normotensives (by random effects 34.2 mmol/
24 hrs, 95% CI: 18.8 to 49.6, Chi² p-value = 0.03, I² = 76%),
hypertensive (by fixed effects 39.1 mmol/24 hrs, 95% CI: 31.1
to 47.1, Chi² p-value = 0.35; I² = 0%) and heart failure (by 27.0
mmol/24hrs, 95% CI: 24.5 to 29.5). See Analysis 1.7
Health-related quality of life
No studies reported outcomes using a validated health-related
quality of life instrument.
Subgroup analyses and investigation of heterogeneity
In order to take to take account of the heterogeneity in popula-
tions and CV baseline risk, we stratified meta-analyses according
to whether studies were undertaken in normotensive, hyperten-
sive or heart failure populations. However, there was insufficient
variability and number of studies to formally investigate hetero-
geneity. For example, as all studies applied participant level salt
reduction interventions, we were unable to compare the effect of
individual vs. population level interventions.
Small study bias
Given the small number of included studies it was not possible to
assess small study bias using either funnel plot or statistically.
D I S C U S S I O N
Summary of main results
This Cochrane review identified seven randomised controlled tri-
als that assessed the long-term (> six-months) effects of interven-
tions aimed at reducing dietary salt on mortality and cardiovas-
cular morbidity. Three trials were in normotensives (HPT 1989
[36 mo], TOHP I 1992 [18 mo]; TOHP II 1997 [36 mo], n=
3518participants), two inhypertensives (Morgan 1978 [7-71mo];
TONE 1998 [30 mo], n=758 participants), one in a mixed pop-
ulation of normo- and hypertensives (Chang 2006 [31 mo], n=
1981 participants) and one in heart failure (Paterna 2008 [6.4
mo], n=232 participants).
We found no strong evidence that salt reduction reduced all-cause
mortality in normotensives (end of trial RR 0.67, 95% CI 0.40
to 1.12, 60 deaths, 3518 participants; longest follow up - relative
risk: 0.90, 95% CI: 0.58 to 1.40, 79 deaths, 3518 participants)
or hypertensives (end of trial - relative risk: 0.97, 95% CI 0.83 to
1.13, 513 deaths, 2058 participants; longest follow up - relative
risk: 0.96, 95%CI; 0.83 to 1.11, 565 deaths, 2349 participants). A
single RCT showed increase the risk of all-cause death in one study
(relative risk: 2.59, 95% 1.04 to 6.44, 21 deaths, 232 participants)
in those with congestive heart failure receiving a low salt diet. Few
cardiovascular events were reported, and the lack of a statistically
significant effect of reduced salt on cardiovascular morbidity in
people with normal blood pressure (end of trial - relative risk:
0.71, 95% CI: 0.42 to 1.20, 200 events, 2502 participants) and
high blood pressure (end of trial - relative risk: 0.84, 95%CI: 0.57
to 1.23, 93 events, 720 participants). We found no information
on participant’s health-related quality of life assessed using either
validated generic or disease-specific instruments.
The interventions were capable of reducing urinary sodium ex-
cretion and indicated that participants continued to comply with
sodium restriction in the long-term, at least to some degree, al-
though, as noted in a previous Cochrane review, the degree of
sodium restriction is likely to attenuate over time (Hooper 2004).
End of trial systolic and diastolic blood pressure were reduced by
an average of some 1 mmHg in normotensives and by an average
of 2 to 4 mmHg in hypertensives and those with heart failure.
Sustained long-term reductions of blood pressure of 1 and 4
mmHg would be predicted to reduce CVD mortality by 5% and
20% respectively (MacMahon 1990).Our point estimates are con-
sistent with effects of this size but have wide confidence intervals
owing to the relatively small number of events.
Overall completeness and applicability of
evidence
A previous Cochrane review was limited by the lack of reported
events (17 deaths, 93 cardiovascular events) (Hooper 2004). In
this review, because of longer observational follow up (up to 10 to
15-years) of three of the trials included in the previous Cochrane
review (TOHP I 1992 [11.5 yrs]; TOHP II 1997 [8 yrs]; TONE
1998 [12.7 yrs]) and inclusion of two more recent RCTs (Chang
2006 [31 mo]; Chang 2006 [31 mo]; Paterna 2008 [6.4 mo])
we have gathered more evidence on mortality and cardiovascu-
lar outcomes (~6,500 participants, 665 deaths, 293 cardiovascular
events). Nevertheless the total amount of evidence on events re-
mains limited. Assuming a control risk of 14% (hypertension trial
control event risk in present review) we would require some 2500
cardiovascular events in over 18,000 trial participants to detect a
small reduction in relative risk (0.90) with dietary salt advice (at
80% power and 5% alpha).
Although a relatively small evidence base, the external validity of
the review was potentially high. Most studies included men and
women at varying levels of risk of cardiovascular risk, primarily
free-living in a community setting in industrialised countries. One
study was undertaken in veterans in a residential setting in Taiwan,
a recently graduated developing economy (Chang 2006 [31 mo]).
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Quality of the evidence
Although all included studies were randomised controlled trials,
only one of the seven included studies provided sufficient detail to
be judged as having adequate random sequence generation, allo-
cation concealment and outcome blinding. Nevertheless, all trials
provided evidence of baseline balance. Although lack of blinding
is unlikely to alter outcome assessment when outcomes include
mortality and cardiovascular events, failure to blind participants
may have lead to a positive change the lifestyle and dietary be-
haviours of control participants, leading to a reduction in the dif-
ference between groups.
Most trials appeared to be free from dietary changes in the inter-
vention and control group apart from dietary sodium. The one
major exceptionwas the trial byChangwhere sodiumwas replaced
by a high potassium substitute (Chang 2006 [31 mo]). Potassium
has effects on blood pressure andmay have deleterious effects in in-
dividuals with renal disease (Cappuccio 2000). Two studies in hy-
pertensives allowed changes in anti-hypertensive medication dur-
ing the period of the trial (Morgan 1978 [7-71 mo]; TONE 1998
[30 mo]). In both trials, lower levels of hypertensive medication
in the intervention group compared to control may have reduced
the blood pressure lowering effect of reduced dietary sodium and
therefore offset mortality and cardiovascular morbidity benefits.
By incorporating data from the longest follow up point, we sought
to maximise the opportunity to capture all deaths and cardiovas-
cular events that were affected by alterations in dietary salt, not just
those within the RCT period. However, in doing so we may have
introduced a major source of bias. For three large studies (TOHP
I 1992 [11.5 yrs], TOHP II 1997 [8 yrs], TONE 1998 [12.7 yrs])
the longest follow up was considerably beyond the official end of
the trial and therefore observational. It was unclear if the inter-
vention groups continued their low salt diets and whether control
groups were left to continue with dietary advice or advised to re-
duce their salt. For this reason we included the primary analysis in
each case as the latest data trial end, more robust but with slightly
fewer deaths and cardiovascular events.
In summary, the overall internal validity of the evidence base in
this review was limited and therefore our conclusions regarding
the effect of a reduction in dietary salt may not be robust.
Potential biases in the review process
We searched comprehensively for randomised controlled trials of
dietary sodium reduction, with a duration of 6-months or more
and that reportedmortality or cardiovascular events.We attempted
to contact all authors of included studies to verify events. Never-
theless, we were unable to report all relevant outcomes for all trials.
The small number of included studies prevented us from being
able to assess the presence of small study or publication bias.
In common with previous systematic reviews of dietary interven-
tions, we observed marked heterogeneity across studies in terms
of their population, sample size and follow up. Whilst we strat-
ified meta-analysis by differing sub-populations (normotensives,
hypertensives and congestive heart failure) and pooled studies us-
ing weighting based on sample size we did not account for the du-
ration of follow up. A previous Cochrane review (Hooper 2004)
suggests that over time the sodium reduction achieved is greatly
reduced, as is the effect on blood pressure and therefore the effect
on events potentially diminished.
Agreements and disagreements with other
studies or reviews
Our finding of a lack of strong evidence of an effect of dietary
sodium reduction onmortality and cardiovascular events is in con-
trast to Starzzullo 2009 who systematically reviewed prospective
observational studies that examined the relationship between di-
etary sodium and cardiovascular events. They included 13 cohort
studies (177,025 participants) over follow up three-17 years and
found higher salt intake to be associated with greater risk of stroke
(pooled relative risk: 1.23, 95% CI: 1.06 to 1.43, 5161 events)
and cardiovascular events (pooled relative risk: 1.14, 95%CI: 0.99
to 1.32, 5346 events). Total and cardiovascular mortality were not
reported. The inherent limitation of the Starzzullo review is the
observational nature of the evidence i.e. studies describe the life
course of persons who follow a chosen diet but provide no infor-
mation about what might happen if that diet were experimentally
allocated. People who choose a lower salt diet are likely to also eat
a diet of fresh foods, lower in fats and refined carbohydrate, take
more exercise and be less likely to smoke, so that their lower levels
of deaths and disease may not relate to salt intake at all.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our findings are consistent with the belief that salt reduction is
beneficial in normotensive and hypertensive people. However, the
methods of achieving salt reduction in the trials included in our
review, and other systematic reviews, were relatively modest in
their impact on sodium excretion and on blood pressure levels,
generally required considerable efforts to implement and would
not be expected to have major impacts on the burden of CVD.
The challenge for clinical and public health practice is to find
more effective interventions for reducing salt intake that are both
practicable and inexpensive.
Many countries have national authoritative recommendations,
often sanctioned by government, that call for reduced dietary
sodium. In UK, the National Institute of Health and Clinical
Guidance (NICE) has recently called for an acceleration of the re-
duction in salt in the general population from a maximum intake
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of 6 g per day per adult by 2015 and 3 g by 2025 (NICE 2010).
Despite collating more events than previous systematic reviews of
randomised controlled trials (565 deaths in almost 7,000 partici-
pants) we were unable to demonstrate a robustly estimated effect
of reduced dietary salt on mortality or cardiovascular morbidity
in normotensive or hypertensive populations. Including a further
79 deaths from long-term observational follow up of three trials
did not improve the statistical power of the meta-analysis which is
underpowered to assess the likely small relative risk reductions on
all-cause mortality or cardiovascular events of dietary salt restric-
tion.
Implications for research
In accord with the research recommendation of a previous
Cochrane review, three of the large trials (TOHP I, TOHP II,
TONE) have assessed the long-term effects of reduced dietary
salt advice on mortality and cardiovascular morbidity. Our find-
ings support the recent call for further rigorous large long-term
randomised controlled trials, capable of definitively demonstrat-
ing the cardiovascular benefit of dietary salt reduction (Alderman
2010). Such trials need to assess population level interventions
that are likely to lead to sustained reductions in salt intake and
are commensurate with current public health guidelines. Further
RCT evidence is needed to assess whether dietary restriction of
sodium is harmful for people with heart failure. It will be impor-
tant to evaluate the effects of voluntary salt reductions by food
industries as these may hold greater opportunities for practicable
and inexpensive means of reducing salt intake in the population
at large than focusing on dietary advice for individuals.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chang 2006 [31 mo]
Methods Cluster RCT [5 kitchens]
Participants N Randomised: 1991 (N=768, intervention, 2 kitchens; N=1213 control, 3 kitchens)
Baseline Blood Pressure: Int.: SBP mean 131.3 (SD 19.7), DBP mean 71.2 (SD 10.8)
; Ctrl: SBP mean 130.7 (SD 20.4), DBP mean 71.4 (SD 10.8)
Case mix: Int.: 40.2% hypertension; Ctrl.: 40.4% hypertension
Age: mean 75.6 (SD 7.7), 74.8 (7.0), 74.8 (7.3), 74.6 (6.7), 74.6 (6.1) in kitchens 2
and 3 (int. group), and 1, 4, and 5 (ctrl group) respectively.
CV diagnoses: None reported
Percentage male: 100%
Percentage white: Not reported.
Inclusion/exclusion criteria:
Inclusion: Veterans registered into a retired home in Northern Taiwan.
Exclusion: Bed-ridden veterans, high serum creatinine (i.e. >=3.5mg/dL)
Interventions Intervention
Total duration: Average of 31 months.
Salt reduction/advice component: Ate food prepared by the cook of the kitchen to
which they were assigned, using salt containing 49% sodium chloride, 49% potassium
chloride, and 2% other additives. The ’potassium enriched salt’ replaced the regular salt
in the selected kitchens in a gradual manner. It was mixed with regular salt in a 1:3 ratio
for the first week, it was then increased to 1:1 for the second week, and 3:1 for the third
week. By the fourth week cooks used solely the potassium enriched salt.
Other dietary component: Other condiments and spices such as soy sauce and
monosodium glutamate were not limited because reasonably priced low-sodium soy
sauce and monosodium glutamate were not available at the time of the trial.
Comparator
Dietary: Ate food prepared by the cook of the kitchen to which they were assigned using
’regular salt’ containing 99.6% sodium chloride and 0.4% other additives at all times.
Other condiments and spices such as soy sauce and monosodium glutamate were not
limited because reasonably priced low-sodium soy sauce and monosodium glutamate
were not available at the time of the trial.
Outcomes Deaths (all cause & CVD)
Notes Outcomes are not reported by kitchen so not able to quantify effect of clustering
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The simplest randomisation method, i.e., drawing lots, was
used.”
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Chang 2006 [31 mo] (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The veterans were told about the trial, but were not told to
which salt they were assigned.”
Yes - participants. Unclear - study personnel and outcome
assessors.
Incomplete outcome data (attrition bias)
All outcomes
High risk It appears that all subjects were followed-up for the deaths
outcome.A consort diagramand reasons for losses to follow-
up for other outcomes are given. No sensitivity analysis or
imputation was carried out to assess the impact of missing
data.
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in the
results.
Assessment of compliance? Low risk Subjects ate food that was prepared for them.
Groups balanced at baseline? Low risk “The ages of persons in different kitchens were not significantly
[different] at entry (P=0.24). The results also indicated that
weight, height, body mass index, blood pressure, and electrolytes
for a subsamples of persons in the experimental and control
groups were not significantly different at baseline. Persons in
[the experimental kitchens] had slightly longer follow-up times
than did their counterparts [in the control kitchens]; however,
the difference did not reach statistical significance (P=0.11).”
Intention to treat analysis? Low risk Not specifically reported, but on the basis of the consort
diagram, subjects did appear to be analysed according to
the groups to which they were originally allocated.
Free from follow up bias? Low risk The dietary intervention was applied over the period of
event outcome follow up
HPT 1989 [36 mo]
Methods Individual RCT
Participants N Randomised: 392 (N=196, intervention, N=196, control)
Baseline Blood Pressure: Int.: SBP mean124.0 (SD NR), DBP mean 82.6 (SD NR);
Ctrl: mean SBP 123.9(SD NR), DBP mean 83.0 (SD NR)
Case mix: normotensives
Age: Int. mean 39.0 (SD NR); Ctrl: mean 38.5 (SD NR)
CV diagnoses: none
Percentage male: 65%
Percentage white: 82%
Inclusion/exclusion criteria:
Inclusion:Men and women aged 25-49yrs; DBP 78-89mmHg
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HPT 1989 [36 mo] (Continued)
Exclusion: Use of antihypertensive medication, evidence of CVD, BMI >=0.0035kg/
cm2, dietary requirements incompatible with any of the interventions, drank 21 or
more alcoholic drinks per week, pregnant women, unable to comply with the protocol
requirements.
Interventions Intervention
Total duration: 36 months
Salt reduction/advice component: Dietary counselling (in groups) aimed at sodium
restriction. The groups met once a week for the first 10 weeks, once every two weeks for
the next four weeks, and then once every month for the rest of treatment and follow-up.
The group goal was a 50% reduction (<= 70mmol) in mean urine sodium. Personnel
delivering the interventions were trained and experienced in effecting behaviour change.
Counselling included a mixture of didactic presentations and demonstrations, token
incentives, telephone calls, and newsletters.
Other dietary component: none stated
Comparator
Dietary: no dietary counselling
Outcomes BP, Urinary Na excretion, Deaths (all cause)
Notes - Factorial design (calorie restriction & potassium supplementation not reported here).
- No difference in proportion of individuals in each group who began hypertensive
medication (8.4% intervention vs. 9/0% control) over 36 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation procedure involved a fixed assignment ratio
design that provided for equal numbers of assignments within clinic
and weight strata in blocks (randomly ordered) of size 3, 6, or 9 for
the normal weight stratum and of size 5 to 10 for the high-weight
stratum.
“Randomisations were performed on demand at the individual
clinic centers (using a pseudo-random number generator provided
with the S/23 BASIC language) with schedules and software for
issuing assignments generated by the DCC.”
Allocation concealment (selection bias) Low risk “Randomisations were performed on demand at the individual
clinic centers (using a pseudo-random number generator provided
with the S/23 BASIC language) with schedules and software for
issuing assignments generated by the DCC. Clinic personnel had to
key all [Baseline 1 and Baseline 2 visit] data and those contained
on part I of the [Baseline 3 visit] data before an assignment could
be obtained (via the S/23)”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “In order to reduce observer bias, data collection and treatment visits
for dietary counselling were not held in the same week for a given
participant, and data collection (i.e., interviews, measurements,
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HPT 1989 [36 mo] (Continued)
food record review, and the like) were carried out by personnel not
involved in treatment.”
“Participants were asked not to [...] divulge or discuss their dietary
counselling with data collection personnel.”
No - participants; Yes - data collectors; Unclear - data analysts.
Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers in each group at each assessment time point were re-
ported. The only reasons given for losses to follow-up were non-
attendance at follow-up visits or death. No sensitivity analysis
or imputation undertaken to assess impact of loss to follow-up.
Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results.
Assessment of compliance? Low risk “Attendance during the first 12 counselling sessions ranged from a
high of 86.5% for the Na treatment group in the sodium-calorie
component at session 1 to a low of 46.8% for that same treatment
group at session 12. Attendance for all counselling groups declined
with time (test for linear decline, P<.001). Generally, attendance
over the 12 sessions was better for the two treatment groups involv-
ing calorie restriction [...] than for the other two dietary treatment
groups [including the sodium reduction group].”
“For the purposes of this article, we use progress toward or attainment
of dietary treatment goals as indices of compliance. [...] As a first
level of exploratory analysis, univariate and multiple linear regres-
sions were conducted comparing 34 baseline and process variables
with urine sodium excretion [....] as [one of the] dependent vari-
ables. [ ....]In the second level of analysis, compliance was defined in
terms of achieving treatment goals. For the sodium reduction groups,
compliance was defined as having a 24-hr urine excretion of less
than or equal to 70mEq.”
Groups balanced at baseline? Low risk “Except for sex there were no marked baseline differences among the
treatment groups.”
Intention to treat analysis? Low risk “All results are presented by original treatment assignment.”
Free from follow up bias? Low risk Duration of intervention same as follow up time for event out-
comes
Morgan 1978 [24 mo]
Methods Individual RCT
Participants N Randomised: 77 (N=35 intervention N=42 control) groups
Baseline Blood Pressure: Int: SBP mean 160 (SD 23), DBP 97 (SD 8); Ctrl: SBP mean
165 (SD 17), DBP mean 97 (SD 8)
Case mix: Untreated hypertensives
Age: Int. mean: 57.1 (SD NR); Ctrl. mean: 58.6 (SD NR)
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Morgan 1978 [24 mo] (Continued)
CV diagnoses: Borderline hypertensives (DBP = 95-109)
Percentage male: 100%
Percentage white: not reported
Inclusion/exclusion criteria:
Inclusion: Males with borderline hypertension on admission to hospital or outpatient
visit
Exclusion:Malignant disease, severe psychiatric disturbances, severe physical incapacity
or a disease likely to be fatal in the next two years, serum-creatinine levels >0.18mmol/
l, abnormal liver-function tests, in cardiac failure or on diuretic therapy.
Interventions Intervention
Total duration: 6 months
Salt reduction/advice component: Patients instructed to reduce their sodium chlo-
ride intake and were given a diet that should have reduced their sodium intake to 70-
100mmol/day. The advice about diet was repeated at 6mths. No details on who gave
advice.
Other dietary component: At each 6mth review visit, if serum potassium levels
<3.4mmol/L, potassium supplements were given.
Comparator
No treatment reviewed at 6 mo (as intervention)
Other: Not given any treatment, but reviewed at six-monthly intervals and if the DBP
rose above 115mmHg treatment was started
Outcomes Deaths (all cause & CVD); BP; Urinary Na Excretion
Notes CV morbidity and CV mortality data taken from previous Cochrane review
Taking antihypertensive medication (at 6 mo): Intervention - 4/10 vs Control - 9/10
(RR: 0.44, 95% CI: 0.20 to 0.98)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[patients] were randomly divided into 4 subgroups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Information regarding life or deathwas not known for two patients,
who were excluded from the study. All patients included in the study
were seen at the initial visit, and at a subsequent six-month visit.
Patients who did not report back on at least one occasion have not
been analysed. Five patients died in the first six months; these have
been included in the analysis. There were no other known deaths
in this time interval in the patients who did not report back. More
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Morgan 1978 [24 mo] (Continued)
than 90% of initially allocated patients reported back at the end of
the first six-month period.”
The only reason given for losses to follow-up was patients not
reporting back.No sensitivity analysis or imputation undertaken
to assess impact of loss to follow-up.
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported at some
point in the results
Assessment of compliance? Low risk Urinary sodium is measured, and although it is not specifically
stated that this was used to assess compliance, it is implied:
“Patients in the dietary therapy group who continued to have a high
sodium excretion were advised about their diet.”
Groups balanced at baseline? Low risk “At the start of the study the groups were similar in age, weight,
height, pulse-rate, and serum electrolytes, urea, creatinine, uric acid,
glucose, and cholesterol. The initial systolic and diastolic blood-
pressures, supine and standing, did not differ among the groups”.
Intention to treat analysis? Low risk Although the term ITT is not used by the authors it appears that
groups were analysed as randomised.
“[Morgan et al.’s (1980)] report does not exclude patients who
changed therapy or ceased therapy. It evaluates the proposition: ‘Did
the decision to implement therapy alter the mortality rate in patients
with mild hypertension’?”
Free from follow up bias? High risk Longest event follow up for mortality was 71 months but last
stated diet advice stated as 6 months.No urinary sodium excre-
tion data available at longest follow up
Morgan 1978 [6 mo]
Methods Individual RCT
Participants N Randomised: 77 (N=35 intervention N=42 control) groups
Baseline Blood Pressure: Int: SBP mean 160 (SD 23), DBP 97 (SD 8); Ctrl: SBP mean
165 (SD 17), DBP mean 97 (SD 8)
Case mix: Untreated hypertensives
Age: Int. mean: 57.1 (SD NR); Ctrl. mean: 58.6 (SD NR)
CV diagnoses: Borderline hypertensives (DBP = 95-109)
Percentage male: 100%
Percentage white: not reported
Inclusion/exclusion criteria:
Inclusion: Males with borderline hypertension on admission to hospital or outpatient
visit
Exclusion:Malignant disease, severe psychiatric disturbances, severe physical incapacity
or a disease likely to be fatal in the next two years, serum-creatinine levels >0.18mmol/
l, abnormal liver-function tests, in cardiac failure or on diuretic therapy.
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Morgan 1978 [6 mo] (Continued)
Interventions Intervention
Total duration: 6 months
Salt reduction/advice component: Patients instructed to reduce their sodium chlo-
ride intake and were given a diet that should have reduced their sodium intake to 70-
100mmol/day. The advice about diet was repeated at 6mths. No details on who gave
advice.
Other dietary component: At each 6mth review visit, if serum potassium levels
<3.4mmol/L, potassium supplements were given.
Comparator
No treatment reviewed at 6 mo (as intervention)
Other: Not given any treatment, but reviewed at six-monthly intervals and if the DBP
rose above 115mmHg treatment was started
Outcomes Deaths (all cause & CVD); BP; Urinary Na Excretion
Notes CV morbidity and CV mortality data taken from previous Cochrane review
Taking antihypertensive medication (at 6 mo): Intervention - 4/10 vs Control - 9/10
(RR: 0.44, 95% CI: 0.20 to 0.98)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[patients] were randomly divided into 4 subgroups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk “Information regarding life or deathwas not known for two patients,
who were excluded from the study. All patients included in the study
were seen at the initial visit, and at a subsequent six-month visit.
Patients who did not report back on at least one occasion have not
been analysed. Five patients died in the first six months; these have
been included in the analysis. There were no other known deaths
in this time interval in the patients who did not report back. More
than 90% of initially allocated patients reported back at the end of
the first six-month period.”
The only reason given for losses to follow-up was patients not
reporting back.No sensitivity analysis or imputation undertaken
to assess impact of loss to follow-up.
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported at some
point in the results
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Morgan 1978 [6 mo] (Continued)
Assessment of compliance? Low risk Urinary sodium is measured, and although it is not specifically
stated that this was used to assess compliance, it is implied:
“Patients in the dietary therapy group who continued to have a high
sodium excretion were advised about their diet.”
Groups balanced at baseline? Low risk “At the start of the study the groups were similar in age, weight,
height, pulse-rate, and serum electrolytes, urea, creatinine, uric acid,
glucose, and cholesterol. The initial systolic and diastolic blood-
pressures, supine and standing, did not differ among the groups”.
Intention to treat analysis? Low risk Although the term ITT is not used by the authors it appears that
groups were analysed as randomised.
“[Morgan et al.’s (1980)] report does not exclude patients who
changed therapy or ceased therapy. It evaluates the proposition: ‘Did
the decision to implement therapy alter the mortality rate in patients
with mild hypertension’?”
Free from follow up bias? High risk Longest event follow up for mortality was 71 months but last
stated diet advice stated as 6 months.No urinary sodium excre-
tion data available at longest follow up
Morgan 1978 [7-71 mo]
Methods Individual RCT
Participants N Randomised: 77 (N=35 intervention N=42 control) groups
Baseline Blood Pressure: Int: SBP mean 160 (SD 23), DBP 97 (SD 8); Ctrl: SBP mean
165 (SD 17), DBP mean 97 (SD 8)
Case mix: Untreated hypertensives
Age: Int. mean: 57.1 (SD NR); Ctrl. mean: 58.6 (SD NR)
CV diagnoses: Borderline hypertensives (DBP = 95-109)
Percentage male: 100%
Percentage white: not reported
Inclusion/exclusion criteria:
Inclusion: Males with borderline hypertension on admission to hospital or outpatient
visit
Exclusion:Malignant disease, severe psychiatric disturbances, severe physical incapacity
or a disease likely to be fatal in the next two years, serum-creatinine levels >0.18mmol/
l, abnormal liver-function tests, in cardiac failure or on diuretic therapy.
Interventions Intervention
Total duration: 6 months
Salt reduction/advice component: Patients instructed to reduce their sodium chlo-
ride intake and were given a diet that should have reduced their sodium intake to 70-
100mmol/day. The advice about diet was repeated at 6mths. No details on who gave
advice.
Other dietary component: At each 6mth review visit, if serum potassium levels
<3.4mmol/L, potassium supplements were given.
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Morgan 1978 [7-71 mo] (Continued)
Comparator
No treatment reviewed at 6 mo (as intervention)
Other: Not given any treatment, but reviewed at six-monthly intervals and if the DBP
rose above 115mmHg treatment was started
Outcomes Deaths (all cause & CVD); BP; Urinary Na Excretion
Notes CV morbidity and CV mortality data taken from previous Cochrane review
Taking antihypertensive medication (at 6 mo): Intervention - 4/10 vs Control - 9/10
(RR: 0.44, 95% CI: 0.20 to 0.98)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[patients] were randomly divided into 4 subgroups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk “Information regarding life or deathwas not known for two patients,
who were excluded from the study. All patients included in the study
were seen at the initial visit, and at a subsequent six-month visit.
Patients who did not report back on at least one occasion have not
been analysed. Five patients died in the first six months; these have
been included in the analysis. There were no other known deaths
in this time interval in the patients who did not report back. More
than 90% of initially allocated patients reported back at the end of
the first six-month period.”
The only reason given for losses to follow-up was patients not
reporting back.No sensitivity analysis or imputation undertaken
to assess impact of loss to follow-up.
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported at some
point in the results
Assessment of compliance? Low risk Urinary sodium is measured, and although it is not specifically
stated that this was used to assess compliance, it is implied:
“Patients in the dietary therapy group who continued to have a high
sodium excretion were advised about their diet.”
Groups balanced at baseline? Low risk “At the start of the study the groups were similar in age, weight,
height, pulse-rate, and serum electrolytes, urea, creatinine, uric acid,
glucose, and cholesterol. The initial systolic and diastolic blood-
pressures, supine and standing, did not differ among the groups”.
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Morgan 1978 [7-71 mo] (Continued)
Intention to treat analysis? Low risk Although the term ITT is not used by the authors it appears that
groups were analysed as randomised.
“[Morgan et al.’s (1980)] report does not exclude patients who
changed therapy or ceased therapy. It evaluates the proposition: ‘Did
the decision to implement therapy alter the mortality rate in patients
with mild hypertension’?”
Free from follow up bias? High risk Longest event follow up for mortality was 71 months but last
stated diet advice stated as 6 months.No urinary sodium excre-
tion data available at longest follow up
Paterna 2008 [6.4 mo]
Methods Individual RCT
Participants N Randomised: 232 (N=114 intervention, N=120 control)
Baseline Blood Pressure: Int: SBP 126 (SD 15), DBP 82 (SD 13); Ctrl: SBP 125 (SD
15), DBP 83 (SD 14)
Case mix: Congestive heart failure
Age: mean 72.6 (SD 8)
CV diagnoses: Treated compensated heart failure
Percentage male: 62%
Percentage white: not reported
Inclusion/exclusion criteria:
Inclusion: Compensated patients hospitalised within previous 30 days for recently de-
compensated CHF. Patients had to have uncompensated CHF, NYHA functional class
IV that was unresponsive to treatment with high doses of oral furosemide up to 250-
500mg/day and/or combinations of diuretics, ACE-inhibitors, digitalis, beta-blockers
and nitrates, and to be under this therapy at least 2 weeks prior to hospitalisation. Pa-
tients also had to have left ventricular ejection fraction (LVEF) <35%, serum creatinine
<2mg/dl, blood urea nitrogen <=60mg/dl, a decreased urinary volume (<500ml/24h)
and low natriuresis (<60mmol/24h), despite receiving established treatments. None of
the patients had to take non-steroidal anti-inflammatory drugs (NSAIDS). All patients
received high-dose furosemide (250-1000mg, twice a day), Hypertonic Saline Solution
(HSS), a normal sodium diet (120mmol) and a decreased fluid intake (1000ml/day)
during hospitalisation. When compensated state was achieved (NYHA class II), patients
received oral furosemide (250-500mg, twice a day), a normal sodium diet (120mmol
sodium) and a fluid intake of 1000ml/day. This continued after discharge, and patients
were considered clinically compensated when they reached a change in NYHA func-
tional class to at least class II and the accomplishment of an ideal body weight. Patients
received tailored therapy after discharge. Only patients in NYHA class II at 30 days after
discharge were included in the study and randomised.
Exclusion: Cerebral vascular disease, dementia, cancer, uncompensated diabetes, and
severe hepatic disease. Patients requiring pacemaker implantation and those with an
alcoholic habit. Patients who declined to take part in the study protocol (but continued
the prescribed treatment), were unable to follow the assigned treatment, did not follow
the treatment protocol or attend the scheduled clinic visits, did not adhere to the fluid
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Paterna 2008 [6.4 mo] (Continued)
intake of 1000ml/day, or had a reduction or discontinuation of prescribed treatments.
Also, patients experiencing side effects of ACE-inhibitor treatment, even if these patients
were given angiotensin II receptor blockers.
Interventions Intervention
Total duration: 6.2 months
Salt reduction/advice component: low sodium diet (80mmol/day). Multiple written
standard diets prepared by dieticians.
Other dietary component: none stated
Other: Oral furosemide 250-500mg b.i.d.
Comparator
Dietary: normal sodium diet (120mmol/day) (same diets as the intervention group with
the addition of 40mmol of sodium/day)
Other: Oral furosemide 250-500mg b.i.d.
“all patients received same amount of saturated fat, fruit and vegetables etc”
Outcomes Mortality, readmissions for worsening CHF, BP, 24 hour urinary sodium excretion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was carried out using a preliminary computer al-
gorithm?”
Allocation concealment (selection bias) Unclear risk “randomisation was performed by an external team of physicians
blinded to the study protocol”
Blinding (performance bias and detection
bias)
All outcomes
High risk “Although we attempted to perform a double-blind study, this was
not possible because the patients receiving the prescribed diets per-
ceived the difference in the amount of salt in the two diets. Another
set of different physicians, also blinded to the study protocol, per-
formed the evaluation of the programmed controls and evaluated
the readmitted CHF patients during follow-up. The laboratory and
neurohormonal controls were also performed by physicians blinded
to the study protocol. The adherence to diet, fluid intake and doses
of furosemide were also controlled by two physicians blinded to the
study protocol. All of these physicians communicated the controlled
results after the conclusion of the study.”
No - Participants.
Unclear - Study personnel and outcome assessors.
Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers in each group at each assessment time point were re-
ported. Reasons for losses to follow-up were not given at each
stage, although it looks likely that they were deaths. No sensi-
tivity analysis or imputation undertaken to assess impact of loss
to follow-up.
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Paterna 2008 [6.4 mo] (Continued)
Selective reporting (reporting bias) Low risk Yes - clinical outcomes. Serum chloride, bicarbonate, albumin,
urea and glucose outcomes are not reported, but these are not
main outcomes.
Assessment of compliance? Low risk “In addition, patients were also contacted every week during fol-
low-up by physicians and dieticians for a telephone interview to
determine the adherence to the reduced fluid intake as well as the
prescribed diet.”
Groups balanced at baseline? Low risk Not specifically stated in the publication, but they appear to be
from table 1.
Intention to treat analysis? Low risk “Analysis was by intention to treat”
Free from follow up bias? Low risk Patients received intervention for same duration as follow up
TOHP I 1992 [11.5 yrs]
Methods Individual RCT
Participants N Randomised: 744 (327 intervention & 417 control)
Baseline Blood Pressure: Int: SBP mean 124.8 (SD 8.5), DBP mean 83.7 (SD 2.7);
Ctrl: SBP mean 125.1 (SD 8.1), mean DBP 83.9 (SD 2.8)
Case mix: Normotensives
Age: Int.: 43.4 (SD 6.6); Ctrl.: 42.6 (SD 6.5)
CV diagnoses: None
Percentage male: 71.4%
Percentage white: 77.2%
Inclusion/exclusion criteria:
Inclusion: aged 30-54: mean DBP 80-89mmHg without antihypertensive medication;
ability to complete and return a satisfactory 24-hour urine collection and food frequency
questionnaire.
Exclusion: Long list of exclusion criteria, generally designed to eliminate patients with:
evidence of medically diagnosed hypertension (DBP >= 90mmHg or use of BP med-
ications within 2mths of first evaluation), cardiovascular or other life-threatening or
disabling diseases, gross obesity (BMI>36.14), a contraindication to any of the phase I
interventions, or might have difficulty complying with the treatment or follow-up re-
quirements of the trial.
Interventions Intervention
Total duration: 18mths
Salt reduction/advice component: Dietary and behavioural counselling on how to
identify sodium in the diet, self-monitor intake, and select or prepare low sodium foods
and condiments suited to personal preferences. Individual and weekly group counselling
sessions were provided during the first 3mths, with additional less frequent counselling
and support for the remainder of follow-up. Sessions were provided by nutritionists,
psychologists, or other experienced counsellors. The objective was to reduce urinary
sodium excretion in the intervention group to 80mmol/24h.
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Comparator
Dietary: Usual diet. General guidelines for healthy eating were given.
Outcomes All cause mortality, CV morbidity, BP and 24hr urinary sodium excretion
Notes TOHP I design included allocation to other interventions (weight loss, stress manage-
ment & supplements e.g.. fish oil)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “the clinic notified the coordinating center [of participant eligibility]
by telephone and obtained a randomisation assignment. Clinics
were also provided with sealed envelopes containing randomization
assignments for use when telephone contact with the coordinating
center was not possible.”
“adherence to the appropriate assignment sequence was monitored
by the coordinating center.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “To minimize bias, [BP] observers were blinded to treatment al-
location. Persons certified to measure BP were not involved with
intervention aspects of the trial, nor were they allowed access to data
that would reveal group assignment. When possible, separate facil-
ities or entrances were used for data collection visits as compared to
intervention visits.”
“In order to reduce observer bias, data collectors were blinded to the
treatment assignment of the participants.”
No - participants; Yes - data collectors; Unclear - data analysts.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “In the analyses shown, participants with no follow-up visits [...]
were assigned a zero value for BP change (“intention-to-treat” anal-
ysis). These results did not differ appreciably from those in which
missing BP values were treated as missing at random and excluded
from the analysis.”
“The effect of missing urinary sodium excretion data at follow-
up on estimates of the absolute change from baseline was assessed
by assuming no change (the baseline sodium excretion value was
imputed). To reduce the likelihood that estimates of treatment group
differences were influenced by the inclusion of incomplete samples,
mean differences in urinary sodium excretion at 6, 12, and 18
months were recalculated excluding urine values associated with
a volume less than 500g or, in separate analyses , associated with
creatinine or creatinine per kilogram of body weight less than 85%
of the within-person average.Mean treatment group differences with
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these exclusions were very similar to each other and to those calculated
when all samples were included.”
Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results.
Assessment of compliance? Low risk “Twenty-four-hour urine samples were used to monitor sodium re-
duction” [....] In addition, food frequency questionnaire and 24-
hour dietary recall estimates of sodium intake were obtained from
all life-style participants.”
“Compliance with the three life-style interventions was satisfactory,
both in terms of attendance at counselling sessions and in reaching
specific goals. [...] The group difference [in urinary Na excretion]
was maximal (58mmol/24h) at 6 months, [...] the mean reduction
[in urinary Na excretion] was well-maintained.”
“The Data Coordinating Center provided guidelines for estimating
adherence to the counselling goal of 60mmol sodium /24hr from the
average sodium excretion in two 8-hour urine samples collected at
least 2 days apart.”
Groups balanced at baseline? Low risk “Baseline characteristics were evenly distributed, except for age,
which was higher in the sodium reduction intervention group”
Intention to treat analysis? Low risk “In a sensitivity analysis using logistic regression we performed an
intention to treat analysis treating non-responders as non-events
Because mortality follow-up was virtually complete, we included
all randomised participants in analyses of mortality alone in a full
intention to treat analysis.”
Free from follow up bias? High risk Longest event follow up for mortality and CV morbidity was
~11.5 years but last stated diet advice stated as 18 months. No
urinary sodium excretion data available at longest follow up
TOHP I 1992 [18 mo]
Methods Individual RCT
Participants N Randomised: 744 (327 intervention & 417 control)
Baseline Blood Pressure: Int: SBP mean 124.8 (SD 8.5), DBP mean 83.7 (SD 2.7);
Ctrl: SBP mean 125.1 (SD 8.1), mean DBP 83.9 (SD 2.8)
Case mix: Normotensives
Age: Int.: 43.4 (SD 6.6); Ctrl.: 42.6 (SD 6.5)
CV diagnoses: None
Percentage male: 71.4%
Percentage white: 77.2%
Inclusion/exclusion criteria:
Inclusion: aged 30-54: mean DBP 80-89mmHg without antihypertensive medication;
ability to complete and return a satisfactory 24-hour urine collection and food frequency
questionnaire.
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Exclusion: Long list of exclusion criteria, generally designed to eliminate patients with:
evidence of medically diagnosed hypertension (DBP >= 90mmHg or use of BP med-
ications within 2mths of first evaluation), cardiovascular or other life-threatening or
disabling diseases, gross obesity (BMI>36.14), a contraindication to any of the phase I
interventions, or might have difficulty complying with the treatment or follow-up re-
quirements of the trial.
Interventions Intervention
Total duration: 18mths
Salt reduction/advice component: Dietary and behavioural counselling on how to
identify sodium in the diet, self-monitor intake, and select or prepare low sodium foods
and condiments suited to personal preferences. Individual and weekly group counselling
sessions were provided during the first 3mths, with additional less frequent counselling
and support for the remainder of follow-up. Sessions were provided by nutritionists,
psychologists, or other experienced counsellors. The objective was to reduce urinary
sodium excretion in the intervention group to 80mmol/24h.
Comparator
Dietary: Usual diet. General guidelines for healthy eating were given.
Outcomes All cause mortality, CV morbidity, BP and 24hr urinary sodium excretion
Notes TOHP I design included allocation to other interventions (weight loss, stress manage-
ment & supplements e.g.. fish oil)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “the clinic notified the coordinating center [of participant eligibility]
by telephone and obtained a randomisation assignment. Clinics
were also provided with sealed envelopes containing randomization
assignments for use when telephone contact with the coordinating
center was not possible.”
“adherence to the appropriate assignment sequence was monitored
by the coordinating center.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “To minimize bias, [BP] observers were blinded to treatment al-
location. Persons certified to measure BP were not involved with
intervention aspects of the trial, nor were they allowed access to data
that would reveal group assignment. When possible, separate facil-
ities or entrances were used for data collection visits as compared to
intervention visits.”
“In order to reduce observer bias, data collectors were blinded to the
treatment assignment of the participants.”
No - participants; Yes - data collectors; Unclear - data analysts.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk “In the analyses shown, participants with no follow-up visits [...]
were assigned a zero value for BP change (“intention-to-treat” anal-
ysis). These results did not differ appreciably from those in which
missing BP values were treated as missing at random and excluded
from the analysis.”
“The effect of missing urinary sodium excretion data at follow-
up on estimates of the absolute change from baseline was assessed
by assuming no change (the baseline sodium excretion value was
imputed). To reduce the likelihood that estimates of treatment group
differences were influenced by the inclusion of incomplete samples,
mean differences in urinary sodium excretion at 6, 12, and 18
months were recalculated excluding urine values associated with
a volume less than 500g or, in separate analyses , associated with
creatinine or creatinine per kilogram of body weight less than 85%
of the within-person average.Mean treatment group differences with
these exclusions were very similar to each other and to those calculated
when all samples were included.”
Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results.
Assessment of compliance? Low risk “Twenty-four-hour urine samples were used to monitor sodium re-
duction” [....] In addition, food frequency questionnaire and 24-
hour dietary recall estimates of sodium intake were obtained from
all life-style participants.”
“Compliance with the three life-style interventions was satisfactory,
both in terms of attendance at counselling sessions and in reaching
specific goals. [...] The group difference [in urinary Na excretion]
was maximal (58mmol/24h) at 6 months, [...] the mean reduction
[in urinary Na excretion] was well-maintained.”
“The Data Coordinating Center provided guidelines for estimating
adherence to the counselling goal of 60mmol sodium /24hr from the
average sodium excretion in two 8-hour urine samples collected at
least 2 days apart.”
Groups balanced at baseline? Low risk “Baseline characteristics were evenly distributed, except for age,
which was higher in the sodium reduction intervention group”
Intention to treat analysis? Low risk “In a sensitivity analysis using logistic regression we performed an
intention to treat analysis treating non-responders as non-events
Because mortality follow-up was virtually complete, we included
all randomised participants in analyses of mortality alone in a full
intention to treat analysis.”
Free from follow up bias? High risk Longest event follow up for mortality and CV morbidity was
~11.5 years but last stated diet advice stated as 18 months. No
urinary sodium excretion data available at longest follow up
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Methods Individual RCT
Participants N Randomised: 2382 (1191 intervention; 1191 control)
Baseline Blood Pressure: Int: mean SBP 127.5 (SD 6.6), DBP mean 86.0 (SD 1.9);
Ctrl: SBP mean 127.4 (SD 6.2), DBP SD 85.9 (SD 1.9)
Case mix: Normotensives
Age: Int.: mean 43.9 (SD 6.2); Ctrl.: mean 43.3 (SD 6.1)
CV diagnoses: None
Percentage male: 65.7%
Percentage white: 79.3%
Inclusion/exclusion criteria:
Inclusion: 30-54 year old adults with no evidence of medically diagnosed hyperten-
sion who were moderately overweight (men: between 26.1-37.4kg/m2 ; women: be-
tween 24.4-37.4kg/m2), and had average DBP between 83-89mmHg, and an SBP
<140mmHg. Participants also had to demonstrate compliance with the more difficult
data collection tasks.
Exclusion: Evidence of current hypertension. History of CVD, diabetes mellitus, ma-
lignancy other than nonmelanoma skin cancer during the past 5yrs, or any other serious
life-threatening illness that requires regular medical treatment. Current use of prescrip-
tion medications that affect BP, as well as non-prescription diuretics. Serum creatinine
level >= 1.7mg/dL for men or 1.5mg/dL for women, or casual serum glucose >=200mg/
dL. Current alcohol intake >21 drinks/wk. Pregnancy, or intent to become pregnant
during the study. Plans to move or inability to cooperate.
Interventions Intervention
Total duration: 36 mths
Salt reduction/advice component: Individual and weekly group counselling sessions
were provided initially followed by additional less intensive counselling and support for
the remainder of follow-up. Mini-modules to reinforce the content of the counselling
sessionwere offered in the later years of the intervention. The content of sessions included
sodium information, self-management and social support components. Sessions were
provided by registered dieticians mainly, plus a few psychologists, or other experienced
counsellors. The objective was to reduce urinary sodium excretion in the intervention
group to 80mmol/24h.
Other: The salt reduction intervention was combined with a weight loss intervention or
alone.
Comparator
Dietary: No advice
Other: Usual care or weight loss intervention alone.
Outcomes All causemortality CVmorbidity (a composite ofmyocardial infarction, stroke, coronary
revascularisation or CV death), BP, urinary excretion
Notes This study had a 2x2 factorial design in which the groups were: weight loss alone, sodium
reduction alone, a combination of weight loss and sodium reduction, and a usual care
group. The long term effects of the sodium reduction intervention were analysed by
grouping data for the two sodium reduction interventions (alone or with weight loss)
and for the two non-sodium reduction groups (usual care and weight loss alone)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “The clinic then notified the coordinating center [of participant
eligibility] by telephone and obtained a randomisation assignment.
In those cases where random assignment was not done by phone,
clinics also were provided with sealed randomization envelopes for
use when contact with the coordinating center was not possible.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “With respect to the determination of categorical end points, in
order to minimize bias in the ascertainment of hypertension, an
Endpoints Subcommittee conducts a blind review of study forms, and
as necessary, the medical records of participants who are considered
to have had hypertensive events. Potential hypertensive end points
identified are either confirmed or refuted by the subcommittee.”
“[Data collectors] were masked to participants’ intervention assign-
ments.”
No - participants; Yes - data collectors; Unclear - data analysts
Incomplete outcome data (attrition bias)
All outcomes
Low risk “For those with BP measurements but without urinary sodium ex-
cretion data at the corresponding follow-up visit, a 0 change in uri-
nary sodium excretion was imputed in a secondary analysis.”
“For the small number of participants with no useable BP readings
after randomisation (n=99, of whom 57% were treated early with
BP medications by their physicians), measures from a randomly
selected participant in the usual care group were imputed under
the assumption that having little or no exposure to the intervention
programs would produce similar results to that of the usual care
group.”
Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results.
Assessment of compliance? Low risk “Intervention attendance also is collected for participants within
each of the active intervention groups. The dietary data are collected
on random samples of equal numbers of participants across the treat-
ment groups. The 24-hour urine specimens for sodium, potassium
and creatinine measurements are collected from all participants at
18 and 36months. An additional 24-hour urine specimen, collected
on a 25% sample of trial participants at 6 months, was added to
more fully assess sodium intakes at this time as compared to baseline
levels.”
“Urinary sodium excretion and weight change are collected as in-
termediate end points for all participants. These intermediate end
points were selected to evaluate compliance to specific interventions”
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Groups balanced at baseline? Low risk “Baseline characteristics were evenly distributed, except for age,
which was higher in the sodium reduction intervention group”
Intention to treat analysis? Low risk “In a sensitivity analysis using logistic regression we performed an
intention to treat analysis treating non-responders as non-events.
Because mortality follow-up was virtually complete, we included
all randomised participants in analyses of mortality alone in a full
intention to treat analysis.”
Free from follow up bias? Unclear risk Longest event follow up for mortality and CV morbidity was
~8years but last stated diet advice stated as 36 months. No uri-
nary sodium excretion data available at longest follow up
TOHP II 1997 [8 yrs]
Methods Individual RCT
Participants N Randomised: 2382 (1191 intervention; 1191 control)
Baseline Blood Pressure: Int: mean SBP 127.5 (SD 6.6), DBP mean 86.0 (SD 1.9);
Ctrl: SBP mean 127.4 (SD 6.2), DBP SD 85.9 (SD 1.9)
Case mix: Normotensives
Age: Int.: mean 43.9 (SD 6.2); Ctrl.: mean 43.3 (SD 6.1)
CV diagnoses: None
Percentage male: 65.7%
Percentage white: 79.3%
Inclusion/exclusion criteria:
Inclusion: 30-54 year old adults with no evidence of medically diagnosed hyperten-
sion who were moderately overweight (men: between 26.1-37.4kg/m2 ; women: be-
tween 24.4-37.4kg/m2), and had average DBP between 83-89mmHg, and an SBP
<140mmHg. Participants also had to demonstrate compliance with the more difficult
data collection tasks.
Exclusion: Evidence of current hypertension. History of CVD, diabetes mellitus, ma-
lignancy other than nonmelanoma skin cancer during the past 5yrs, or any other serious
life-threatening illness that requires regular medical treatment. Current use of prescrip-
tion medications that affect BP, as well as non-prescription diuretics. Serum creatinine
level >= 1.7mg/dL for men or 1.5mg/dL for women, or casual serum glucose >=200mg/
dL. Current alcohol intake >21 drinks/wk. Pregnancy, or intent to become pregnant
during the study. Plans to move or inability to cooperate.
Interventions Intervention
Total duration: 36 mths
Salt reduction/advice component: Individual and weekly group counselling sessions
were provided initially followed by additional less intensive counselling and support for
the remainder of follow-up. Mini-modules to reinforce the content of the counselling
sessionwere offered in the later years of the intervention. The content of sessions included
sodium information, self-management and social support components. Sessions were
provided by registered dieticians mainly, plus a few psychologists, or other experienced
counsellors. The objective was to reduce urinary sodium excretion in the intervention
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group to 80mmol/24h.
Other: The salt reduction intervention was combined with a weight loss intervention or
alone.
Comparator
Dietary: No advice
Other: Usual care or weight loss intervention alone.
Outcomes All causemortality CVmorbidity (a composite ofmyocardial infarction, stroke, coronary
revascularisation or CV death), BP, urinary excretion
Notes This study had a 2x2 factorial design in which the groups were: weight loss alone, sodium
reduction alone, a combination of weight loss and sodium reduction, and a usual care
group. The long term effects of the sodium reduction intervention were analysed by
grouping data for the two sodium reduction interventions (alone or with weight loss)
and for the two non-sodium reduction groups (usual care and weight loss alone)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “The clinic then notified the coordinating center [of participant
eligibility] by telephone and obtained a randomisation assignment.
In those cases where random assignment was not done by phone,
clinics also were provided with sealed randomization envelopes for
use when contact with the coordinating center was not possible.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “With respect to the determination of categorical end points, in
order to minimize bias in the ascertainment of hypertension, an
Endpoints Subcommittee conducts a blind review of study forms, and
as necessary, the medical records of participants who are considered
to have had hypertensive events. Potential hypertensive end points
identified are either confirmed or refuted by the subcommittee.”
“[Data collectors] were masked to participants’ intervention assign-
ments.”
No - participants; Yes - data collectors; Unclear - data analysts
Incomplete outcome data (attrition bias)
All outcomes
Low risk “For those with BP measurements but without urinary sodium ex-
cretion data at the corresponding follow-up visit, a 0 change in uri-
nary sodium excretion was imputed in a secondary analysis.”
“For the small number of participants with no useable BP readings
after randomisation (n=99, of whom 57% were treated early with
BP medications by their physicians), measures from a randomly
selected participant in the usual care group were imputed under
the assumption that having little or no exposure to the intervention
programs would produce similar results to that of the usual care
group.”
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Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results.
Assessment of compliance? Low risk “Intervention attendance also is collected for participants within
each of the active intervention groups. The dietary data are collected
on random samples of equal numbers of participants across the treat-
ment groups. The 24-hour urine specimens for sodium, potassium
and creatinine measurements are collected from all participants at
18 and 36months. An additional 24-hour urine specimen, collected
on a 25% sample of trial participants at 6 months, was added to
more fully assess sodium intakes at this time as compared to baseline
levels.”
“Urinary sodium excretion and weight change are collected as in-
termediate end points for all participants. These intermediate end
points were selected to evaluate compliance to specific interventions”
Groups balanced at baseline? Low risk “Baseline characteristics were evenly distributed, except for age,
which was higher in the sodium reduction intervention group”
Intention to treat analysis? Low risk “In a sensitivity analysis using logistic regression we performed an
intention to treat analysis treating non-responders as non-events.
Because mortality follow-up was virtually complete, we included
all randomised participants in analyses of mortality alone in a full
intention to treat analysis.”
Free from follow up bias? Unclear risk Longest event follow up for mortality and CV morbidity was
~8years but last stated diet advice stated as 36 months. No uri-
nary sodium excretion data available at longest follow up
TONE 1998 [12.7 yrs]
Methods Individual RCT
Participants N Randomised: 681 (N=340, intervention &N=341, control) - part of factorial design
study
Baseline Blood Pressure: SBP 128.0 (9.4), DBP 71.3 (7.3) mm Hg
Case mix: Treated hypertensives
Age: 65.8 (SD 4.6)
CV diagnoses: None
Percentage male: 53%
Percentage white: 76%
Inclusion/exclusion criteria:
Inclusion: Healthy, aged 60-80yrs, SBP <145mm Hg &DBP <85mm Hg while tak-
ing a single antihypertensive medication or a single combination regimen consisting
of a diuretic agent and a non-diuretic agent. Individuals taking two antihypertensive
medications were also eligible if they were successfully weaned off one of them during
the screening phase. Independencein activities of daily living. Capacity to alter diet and
physical activity in accordance with the requirements of any TONE intervention.
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Exclusion:Diagnosis or treatment of cancer within the last 5yrs; treatment with diuret-
ics, ACE-inhibitors, or digitalis for CHF or unknown reason; drug therapy with nitrates,
beta blockers, or calcium channel blockers for CHD or reason other than hypertension;
MI or stroke within 6mths; “active” CHD (e.g. angina pectoris); CHF; atrial fibrilla-
tion; second- or third-degree heart block without permanent pacemaker; drug therapy
for ventricular arrhythmias; self-report of heart valve replacement; clinically important
valvular heart disease; insulin dependent diabetes mellitus; severe hypertension; current
or recent (within 6mths) drug therapy for asthma or chronic obstructive lung disease; use
of corticosteroid therapy for >1mth; serious mental or physical illness; unexplained or
involuntary weight loss (>=4.5kg) during the previous year; BMI<21 in men or women,
or >33 in men or >37 in women; serum creatinine >2mg/dL; non-fasting blood glucose
level of >260mg/dL; hyperkalemia (>5.5mmol/L); anaemia (Hb level <110g/L); >14
alcoholic drinks per week (assessed by self-report); severe visual or hearing impairment;
other reason making it difficult for the participant to comply fully with any part of the
study protocol.
Interventions Intervention
Total duration: 4mth “intensive” phase, plus 3mth “extended” phase, and then a main-
tenance phase (duration of this phase is unclear)
Salt reduction/advice component: Individual & group sessions with an interventionist
(typically a registered dietician) who provided information using both centrally and
locally preparedmaterials, motivated participants to make and sustain long-term lifestyle
changes, and frequently monitored progress of groups and individuals. Individualised
feedback was provided. Participants learned about sources of sodium, in particular those
foods with a high salt content, and they learned about possible alternatives. They also
learned how to adapt the recommendations for a low salt diet to their own lifestyle.
The goal of this intervention for the group was to achieve and maintain a 24hr dietary
sodium intake of 80mmol (1800mg) or less (as measured by 24hr urine collection).
Other: Attempt to withdraw hypertensive therapy began 3 months post randomisation
Comparator
Dietary: In order to enhance retention of control participants, meetings were held on a
regular basis with speakers on subjects unrelated to BP, CVD or nutrition
Other: Drug withdrawal began at a comparable time to the intervention group
Outcomes Mortality (all cause & cardiovascular), cardiovascular morbidity (a composite of myocar-
dial infarction, stroke, coronary artery bypass graft (CABG)), BP, urinary sodium
Notes Unpublished all cause mortality data at 12.7 yrs obtained from authors
No data specifically reported on number of individuals who stopped antihypertensive
medication in 2 groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Overweight participants were randomly assigned, in a 2x2 facto-
rial design [...] Nonoverweight participants were randomly assigned
[...]”
“We used a variable block length randomization algorithm.” (from
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investigators)
Allocation concealment (selection bias) Low risk “Assignments were made via computers at the clinic sites, after eligi-
bility criteria were confirmed. The sequences were concealed from
clinic staff?only known to statisticians at the coordinating center.”
(from investigators)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “To facilitate masking of the data collectors, intervention visits were
conducted at separate times and places from the data collection vis-
its.”
“An end point committee, masked to intervention assignment, made
final decisions concerning the end point status of each participant.”
“Outcome information was obtained by staff members who were
blind to the participants’ intervention assignment, at different times
and different locations from those used for the intervention visits.
Participants were instructed not to reveal their intervention assign-
ment to the data collection staff.”
“Intervention staff members were masked with respect to the partic-
ipants’ BP and drug withdrawal status.”
“When questioned at the final follow-up visit, the data collectors
guessed the correct treatment assignment in 31% of the obese par-
ticipants (compared with an expected rate of 25% on the basis of
chance) and in 45% of the nonobese participants (compared with
and expected rate of 50% on the basis of chance).”
No - participants; Yes - data collectors; Unclear - data analysts.
Incomplete outcome data (attrition bias)
All outcomes
High risk The only reason given for losses to follow-up was non-atten-
dance at follow-up visits. No sensitivity analysis or imputation
undertaken to assess impact of loss to follow-up.
Selective reporting (reporting bias) Unclear risk The authors report that data was collected via psychological ques-
tionnaires at randomisation and a number of the follow-up visits,
but none of the data from these appear to be reported, unless they
are in a separate publication.
Assessment of compliance? Low risk “Monitoring adherence (Reduced sodium life-style): Attendance;
urinary data; food and behaviour records; adherence-related incen-
tives.
Monitoring adherence (Usual (control) life-style): Attendance.”
Groups balanced at baseline? Low risk “There was no evidence of a substantial imbalance between the
reduced sodium and UL [usual lifestyle] groups [at baseline]”
Intention to treat analysis? Low risk “Analyses were conducted on an intention-to-treat basis.”
Free from follow up bias? High risk Mortality outcome provided by authors at 12.7 yrs average fol-
low up. No urinary sodium excretion data available at longest
follow up
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Methods Individual RCT
Participants N Randomised: 681 (N=340, intervention &N=341, control) - part of factorial design
study
Baseline Blood Pressure: SBP 128.0 (9.4), DBP 71.3 (7.3) mm Hg
Case mix: Treated hypertensives
Age: 65.8 (SD 4.6)
CV diagnoses: None
Percentage male: 53%
Percentage white: 76%
Inclusion/exclusion criteria:
Inclusion: Healthy, aged 60-80yrs, SBP <145mm Hg &DBP <85mm Hg while tak-
ing a single antihypertensive medication or a single combination regimen consisting
of a diuretic agent and a non-diuretic agent. Individuals taking two antihypertensive
medications were also eligible if they were successfully weaned off one of them during
the screening phase. Independencein activities of daily living. Capacity to alter diet and
physical activity in accordance with the requirements of any TONE intervention.
Exclusion:Diagnosis or treatment of cancer within the last 5yrs; treatment with diuret-
ics, ACE-inhibitors, or digitalis for CHF or unknown reason; drug therapy with nitrates,
beta blockers, or calcium channel blockers for CHD or reason other than hypertension;
MI or stroke within 6mths; “active” CHD (e.g. angina pectoris); CHF; atrial fibrilla-
tion; second- or third-degree heart block without permanent pacemaker; drug therapy
for ventricular arrhythmias; self-report of heart valve replacement; clinically important
valvular heart disease; insulin dependent diabetes mellitus; severe hypertension; current
or recent (within 6mths) drug therapy for asthma or chronic obstructive lung disease; use
of corticosteroid therapy for >1mth; serious mental or physical illness; unexplained or
involuntary weight loss (>=4.5kg) during the previous year; BMI<21 in men or women,
or >33 in men or >37 in women; serum creatinine >2mg/dL; non-fasting blood glucose
level of >260mg/dL; hyperkalemia (>5.5mmol/L); anaemia (Hb level <110g/L); >14
alcoholic drinks per week (assessed by self-report); severe visual or hearing impairment;
other reason making it difficult for the participant to comply fully with any part of the
study protocol.
Interventions Intervention
Total duration: 4mth “intensive” phase, plus 3mth “extended” phase, and then a main-
tenance phase (duration of this phase is unclear)
Salt reduction/advice component: Individual & group sessions with an interventionist
(typically a registered dietician) who provided information using both centrally and
locally preparedmaterials, motivated participants to make and sustain long-term lifestyle
changes, and frequently monitored progress of groups and individuals. Individualised
feedback was provided. Participants learned about sources of sodium, in particular those
foods with a high salt content, and they learned about possible alternatives. They also
learned how to adapt the recommendations for a low salt diet to their own lifestyle.
The goal of this intervention for the group was to achieve and maintain a 24hr dietary
sodium intake of 80mmol (1800mg) or less (as measured by 24hr urine collection).
Other: Attempt to withdraw hypertensive therapy began 3 months post randomisation
Comparator
Dietary: In order to enhance retention of control participants, meetings were held on a
regular basis with speakers on subjects unrelated to BP, CVD or nutrition
Other: Drug withdrawal began at a comparable time to the intervention group
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TONE 1998 [30 mo] (Continued)
Outcomes Mortality (all cause & cardiovascular), cardiovascular morbidity (a composite of myocar-
dial infarction, stroke, coronary artery bypass graft (CABG)), BP, urinary sodium
Notes Unpublished all cause mortality data at 12.7 yrs obtained from authors
No data specifically reported on number of individuals who stopped antihypertensive
medication in 2 groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Overweight participants were randomly assigned, in a 2x2 facto-
rial design [...] Nonoverweight participants were randomly assigned
[...]”
“We used a variable block length randomization algorithm.” (from
investigators)
Allocation concealment (selection bias) Low risk “Assignments were made via computers at the clinic sites, after eligi-
bility criteria were confirmed. The sequences were concealed from
clinic staff?only known to statisticians at the coordinating center.”
(from investigators)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “To facilitate masking of the data collectors, intervention visits were
conducted at separate times and places from the data collection vis-
its.”
“An end point committee, masked to intervention assignment, made
final decisions concerning the end point status of each participant.”
“Outcome information was obtained by staff members who were
blind to the participants’ intervention assignment, at different times
and different locations from those used for the intervention visits.
Participants were instructed not to reveal their intervention assign-
ment to the data collection staff.”
“Intervention staff members were masked with respect to the partic-
ipants’ BP and drug withdrawal status.”
“When questioned at the final follow-up visit, the data collectors
guessed the correct treatment assignment in 31% of the obese par-
ticipants (compared with an expected rate of 25% on the basis of
chance) and in 45% of the nonobese participants (compared with
and expected rate of 50% on the basis of chance).”
No - participants; Yes - data collectors; Unclear - data analysts.
Incomplete outcome data (attrition bias)
All outcomes
High risk The only reason given for losses to follow-up was non-atten-
dance at follow-up visits. No sensitivity analysis or imputation
undertaken to assess impact of loss to follow-up.
Selective reporting (reporting bias) Unclear risk The authors report that data was collected via psychological ques-
tionnaires at randomisation and a number of the follow-up visits,
but none of the data from these appear to be reported, unless they
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TONE 1998 [30 mo] (Continued)
are in a separate publication.
Assessment of compliance? Low risk “Monitoring adherence (Reduced sodium life-style): Attendance;
urinary data; food and behaviour records; adherence-related incen-
tives.
Monitoring adherence (Usual (control) life-style): Attendance.”
Groups balanced at baseline? Low risk “There was no evidence of a substantial imbalance between the
reduced sodium and UL [usual lifestyle] groups [at baseline]”
Intention to treat analysis? Low risk “Analyses were conducted on an intention-to-treat basis.”
Free from follow up bias? High risk Mortality outcome provided by authors at 12.7 yrs average fol-
low up. No urinary sodium excretion data available at longest
follow up
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bentley 2006 Inadequate follow up duration
Knuist 1998 Pregnant women
Koopman 1997 No appropriate outcomes
Licata 2003 Not dietary salt reduction intervention
van der Post 1997 Pregnant women
Velloso 1991 Inadequate follow up duration
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D A T A A N D A N A L Y S E S
Comparison 1. Reduced salt vs control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All cause mortality at end of trial 6 5808 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.84, 1.12]
1.1 Normotensive 3 3518 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.40, 1.12]
1.2 Hypertensive 2 2058 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.83, 1.13]
1.3 Heart Failure 1 232 Risk Ratio (M-H, Fixed, 95% CI) 2.59 [1.04, 6.44]
2 All cause mortality at longest
follow up
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Normotensive 3 3518 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.58, 1.40]
2.2 Hypertensive 3 2349 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.83, 1.11]
2.3 Heart Failure 1 232 Risk Ratio (M-H, Fixed, 95% CI) 2.59 [1.04, 6.44]
3 CV mortality at longest follow
up
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Hypertensive 2 2058 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.45, 1.05]
4 CV morbidity at longest follow
up
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Normotensive 2 2505 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.42, 1.20]
4.2 Hypertensive 2 720 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.57, 1.23]
5 Systolic BP at end of trial 6 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Normotensive 3 2079 Mean Difference (IV, Random, 95% CI) -1.11 [-2.34, 0.11]
5.2 Hypertensive 2 675 Mean Difference (IV, Random, 95% CI) -4.14 [-5.84, -2.43]
5.3 Heart failure 1 211 Mean Difference (IV, Random, 95% CI) -4.0 [-7.27, -0.73]
6 Diastolic BP at end of trial 6 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Normotensive 3 2079 Mean Difference (IV, Random, 95% CI) -0.80 [-1.37, -0.23]
6.2 Hypertensive 2 675 Mean Difference (IV, Random, 95% CI) -3.74 [-8.41, 0.93]
6.3 Heart failure 1 211 Mean Difference (IV, Random, 95% CI) 2.0 [-0.70, 4.70]
7 Urinary sodium excretion at end
of trial
6 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Normotensive 3 1812 Mean Difference (IV, Random, 95% CI) -34.19 [-49.61, -
18.78]
7.2 Hypertensive 2 806 Mean Difference (IV, Random, 95% CI) -39.11 [-47.11, -
31.11]
7.3 Heart failure 1 211 Mean Difference (IV, Random, 95% CI) -27.0 [-29.46, -
24.54]
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Analysis 1.1. Comparison 1 Reduced salt vs control, Outcome 1 All cause mortality at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt vs control
Outcome: 1 All cause mortality at end of trial
Study or subgroup Favours reduced salt Favours control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Normotensive
HPT 1989 [36 mo] 1/196 1/196 0.3 % 1.00 [ 0.06, 15.87 ]
TOHP I 1992 [18 mo] 6/327 12/417 3.7 % 0.64 [ 0.24, 1.68 ]
TOHP II 1997 [36 mo] 16/1191 24/1191 8.3 % 0.67 [ 0.36, 1.25 ]
Subtotal (95% CI) 1714 1804 12.3 % 0.67 [ 0.40, 1.12 ]
Total events: 23 (Favours reduced salt), 37 (Favours control)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Hypertensive
Chang 2006 [31 mo] 192/768 312/1213 84.0 % 0.97 [ 0.83, 1.14 ]
Morgan 1978 [7-71 mo] 4/35 5/42 1.6 % 0.96 [ 0.28, 3.30 ]
Subtotal (95% CI) 803 1255 85.6 % 0.97 [ 0.83, 1.13 ]
Total events: 196 (Favours reduced salt), 317 (Favours control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
3 Heart Failure
Paterna 2008 [6.4 mo] 15/114 6/118 2.0 % 2.59 [ 1.04, 6.44 ]
Subtotal (95% CI) 114 118 2.0 % 2.59 [ 1.04, 6.44 ]
Total events: 15 (Favours reduced salt), 6 (Favours control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.041)
Total (95% CI) 2631 3177 100.0 % 0.97 [ 0.84, 1.12 ]
Total events: 234 (Favours reduced salt), 360 (Favours control)
Heterogeneity: Chi2 = 6.55, df = 5 (P = 0.26); I2 =24%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 6.46, df = 2 (P = 0.04), I2 =69%
0.01 0.1 1 10 100
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Analysis 1.2. Comparison 1 Reduced salt vs control, Outcome 2 All cause mortality at longest follow up.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt vs control
Outcome: 2 All cause mortality at longest follow up
Study or subgroup Favours reduced salt Favours control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Normotensive
HPT 1989 [36 mo] 1/196 1/196 2.4 % 1.00 [ 0.06, 15.87 ]
TOHP I 1992 [11.5 yrs] 10/327 14/417 29.8 % 0.91 [ 0.41, 2.02 ]
TOHP II 1997 [8 yrs] 25/1191 28/1191 67.8 % 0.89 [ 0.52, 1.52 ]
Subtotal (95% CI) 1714 1804 100.0 % 0.90 [ 0.58, 1.40 ]
Total events: 36 (Favours reduced salt), 43 (Favours control)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Hypertensive
Chang 2006 [31 mo] 192/768 312/1213 88.2 % 0.97 [ 0.83, 1.14 ]
Morgan 1978 [7-71 mo] 4/35 5/42 1.7 % 0.96 [ 0.28, 3.30 ]
TONE 1998 [12.7 yrs] 24/144 28/147 10.1 % 0.88 [ 0.53, 1.43 ]
Subtotal (95% CI) 947 1402 100.0 % 0.96 [ 0.83, 1.11 ]
Total events: 220 (Favours reduced salt), 345 (Favours control)
Heterogeneity: Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
3 Heart Failure
Paterna 2008 [6.4 mo] 15/114 6/118 100.0 % 2.59 [ 1.04, 6.44 ]
Subtotal (95% CI) 114 118 100.0 % 2.59 [ 1.04, 6.44 ]
Total events: 15 (Favours reduced salt), 6 (Favours control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.041)
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Analysis 1.3. Comparison 1 Reduced salt vs control, Outcome 3 CV mortality at longest follow up.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt vs control
Outcome: 3 CV mortality at longest follow up
Study or subgroup Favours reduced salt Favours control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypertensive
Chang 2006 [31 mo] 27/768 66/1213 96.6 % 0.65 [ 0.42, 1.00 ]
Morgan 1978 [7-71 mo] 3/35 2/42 3.4 % 1.80 [ 0.32, 10.17 ]
0.01 0.1 1 10 100
Favours reduced salt Favours control
Analysis 1.4. Comparison 1 Reduced salt vs control, Outcome 4 CV morbidity at longest follow up.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt vs control
Outcome: 4 CV morbidity at longest follow up
Study or subgroup Favours reduced salt Favours control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Normotensive
TOHP I 1992 [11.5 yrs] 17/321 32/311 39.9 % 0.51 [ 0.29, 0.91 ]
TOHP II 1997 [8 yrs] 71/938 80/935 60.1 % 0.88 [ 0.65, 1.20 ]
Subtotal (95% CI) 1259 1246 100.0 % 0.71 [ 0.42, 1.20 ]
Total events: 88 (Favours reduced salt), 112 (Favours control)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.71, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Hypertensive
Morgan 1978 [7-71 mo] 6/34 5/33 12.4 % 1.16 [ 0.39, 3.45 ]
TONE 1998 [30 mo] 36/322 46/331 87.6 % 0.80 [ 0.53, 1.21 ]
Subtotal (95% CI) 356 364 100.0 % 0.84 [ 0.57, 1.23 ]
Total events: 42 (Favours reduced salt), 51 (Favours control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
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Analysis 1.5. Comparison 1 Reduced salt vs control, Outcome 5 Systolic BP at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt vs control
Outcome: 5 Systolic BP at end of trial
Study or subgroup Favours reduced salt Favours control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensive
HPT 1989 [36 mo] 174 -2.8 (6.6) 177 -3 (6.7) 30.3 % 0.20 [ -1.19, 1.59 ]
TOHP I 1992 [18 mo] 304 -5.1 (7.9) 395 -3 (8.3) 33.6 % -2.10 [ -3.31, -0.89 ]
TOHP II 1997 [36 mo] 515 -0.7 (9) 514 0.6 (8.5) 36.1 % -1.30 [ -2.37, -0.23 ]
Subtotal (95% CI) 993 1086 100.0 % -1.11 [ -2.34, 0.11 ]
Heterogeneity: Tau2 = 0.78; Chi2 = 6.06, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 1.79 (P = 0.074)
2 Hypertensive
Morgan 1978 [24 mo] 31 -5.5 (22.3) 31 -4 (22.3) 2.4 % -1.50 [ -12.60, 9.60 ]
TONE 1998 [30 mo] 317 -4.6 (11.3) 296 -0.4 (10.5) 97.6 % -4.20 [ -5.93, -2.47 ]
Subtotal (95% CI) 348 327 100.0 % -4.14 [ -5.84, -2.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.75 (P < 0.00001)
3 Heart failure
Paterna 2008 [6.4 mo] 99 107 (13) 112 111 (11) 100.0 % -4.00 [ -7.27, -0.73 ]
Subtotal (95% CI) 99 112 100.0 % -4.00 [ -7.27, -0.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.017)
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Analysis 1.6. Comparison 1 Reduced salt vs control, Outcome 6 Diastolic BP at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt vs control
Outcome: 6 Diastolic BP at end of trial
Study or subgroup Favours reduced salt Favours control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensive
HPT 1989 [36 mo] 174 -2.8 (9.2) 177 -2.9 (9.3) 8.6 % 0.10 [ -1.84, 2.04 ]
TOHP I 1992 [18 mo] 304 -4.4 (5.7) 395 -3.2 (5.8) 43.9 % -1.20 [ -2.06, -0.34 ]
TOHP II 1997 [36 mo] 515 -3 (6.5) 514 -2.4 (7) 47.5 % -0.60 [ -1.43, 0.23 ]
Subtotal (95% CI) 993 1086 100.0 % -0.80 [ -1.37, -0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0057)
2 Hypertensive
Morgan 1978 [24 mo] 31 -5 (11.1) 31 2 (11.1) 34.8 % -7.00 [ -12.53, -1.47 ]
TONE 1998 [30 mo] 317 -2.2 (8) 296 -0.2 (7) 65.2 % -2.00 [ -3.19, -0.81 ]
Subtotal (95% CI) 348 327 100.0 % -3.74 [ -8.41, 0.93 ]
Heterogeneity: Tau2 = 8.34; Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.57 (P = 0.12)
3 Heart failure
Paterna 2008 [6.4 mo] 99 77 (9) 112 75 (11) 100.0 % 2.00 [ -0.70, 4.70 ]
Subtotal (95% CI) 99 112 100.0 % 2.00 [ -0.70, 4.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 1.7. Comparison 1 Reduced salt vs control, Outcome 7 Urinary sodium excretion at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt vs control
Outcome: 7 Urinary sodium excretion at end of trial
Study or subgroup Favours reduced salt Favours control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensive
HPT 1989 [36 mo] 143 -15.96 (68.2) 155 0 (71) 30.2 % -15.96 [ -31.77, -0.15 ]
TOHP I 1992 [18 mo] 232 -55.2 (76.9) 330 -11.3 (77.7) 33.7 % -43.90 [ -56.87, -30.93 ]
TOHP II 1997 [36 mo] 470 -50.9 (86.3) 482 -10.5 (88.5) 36.0 % -40.40 [ -51.50, -29.30 ]
Subtotal (95% CI) 845 967 100.0 % -34.19 [ -49.61, -18.78 ]
Heterogeneity: Tau2 = 139.51; Chi2 = 8.20, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 4.35 (P = 0.000014)
2 Hypertensive
Morgan 1978 [6 mo] 109 157 (87) 58 180 (120) 5.2 % -23.00 [ -57.94, 11.94 ]
TONE 1998 [30 mo] 319 -45 (55.8) 320 -5 (50) 94.8 % -40.00 [ -48.22, -31.78 ]
Subtotal (95% CI) 428 378 100.0 % -39.11 [ -47.11, -31.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 9.58 (P < 0.00001)
3 Heart failure
Paterna 2008 [6.4 mo] 99 76 (7) 112 103 (11) 100.0 % -27.00 [ -29.46, -24.54 ]
Subtotal (95% CI) 99 112 100.0 % -27.00 [ -29.46, -24.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 21.51 (P < 0.00001)
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A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Library 2008 Issue 4
Results for CENTRAL, Health Technology Assessment (HTA) and Database of Abstracts of Reviews of Effect (DARE)
Search Date: 03 November 2008
#1 MeSH descriptor Heart Arrest explode all trees
#2 (cardiac NEAR/3 arrest*):ti,ab,kw
#3 (heart NEAR/3 arrest*):ti,ab,kw
#4 (cardiopulmonary NEAR/3 arrest*):ti,ab,kw
#5 (sudden NEAR/3 death):ti,ab,kw
#6 asystole*:ti,ab,kw
#7 (myocard* NEAR/2 contract*):ti,ab,kw
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 (death* or died or dead or fatal*):ti,ab
#10 mortality:ti,ab.
#11 (#9 OR #10)
#12 MeSH descriptor Cerebrovascular Disorders explode all trees
#13 (stroke* or poststroke* or cva*):ti,ab
#14 (cerebrovascular* or (cerebral adj vascular)):ti,ab
#15 (cerebral or cerebellar or brain* or vertebrobasilar):ti,ab
#16 (infarct* or isch*emi* or thrombo* or emboli* or apoplexy):ti,ab
#17 (cerebral or intracerebral or intracranial or brain* or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid):ti,ab
#18 (haemorrhage or hemorrhage or bleed* or haematoma or hematoma or aneurysm):ti,ab
#19 (#15 AND #16)
#20 (#17 AND #18)
#21 (trans* isch*emic attack*):ti,ab
#22 brain attack:ti,ab
#23 MeSH descriptor Hemiplegia explode all trees
#24 (hemipleg* or hemipar* or post NEXT stroke):ti,ab
#25 (#21 OR #22 OR #23 OR #24)
#26 (#12 OR #13 OR #14 OR #19 OR #20 OR #25)
#27 MeSH descriptor Intermittent Claudication explode all trees
#28 claudica*:ti,ab
#29 MeSH descriptor Peripheral Vascular Diseases explode all trees
#30 MeSH descriptor Vascular Diseases, this term only
#31 (peripher* NEAR/3 (occlu* or arteri* or vascular)):ti,ab
#32 (arterial NEAR/3 (obstruct* or occlus*)):ti,ab
#33 MeSH descriptor Arteriosclerosis Obliterans, this term only
#34 MeSH descriptor Atherosclerosis, this term only
#35 MeSH descriptor Arterial Occlusive Diseases, this term only
#36 ((leg or limb) NEAR/3 (isch*emia or occlusi*)):ti,ab
#37 (arteriosclerosis or atherosclerosis):ti,ab
#38 MeSH descriptor Femoral Artery, this term only
#39 MeSH descriptor Popliteal Artery, this term only
#40 MeSH descriptor Iliac Artery, this term only
#41 ((femoral or renal or iliac) NEAR/3 artery):ti,ab
#42 (occlu* or obstruct*):ti,ab
#43 (#38 OR #39 OR #40 OR #41)
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#44 (#42 AND #43)
#45 (#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37)
#46 (#44 OR #45)
#47 MeSH descriptor Heart Failure explode all trees
#48 MeSH descriptor Myocardial Ischemia explode all trees
#49 angina:ti,ab
#50 (angor pectoris):ti,ab
#51 myocard*:ti,ab
#52 MeSH descriptor Ventricular Dysfunction explode all trees
#53 (ventricular NEAR/2 failure):ti,ab
#54 revascular*:ti,ab
#55 (isch*mi* NEAR/3 heart):ti,ab,kw
#56 coronary:ti,ab,kw
#57 MeSH descriptor Angioplasty explode all trees
#58 MeSH descriptor Angioplasty, Transluminal, Percutaneous Coronary, this term only
#59 (PTCA or angioplast*):ti,ab
#60 MeSH descriptor Myocardial Revascularization, this term only
#61 stenocardia*:ti,ab
#62 (heart NEAR/3 decompensation):ti,ab
#63 MeSH descriptor Myocardial Infarction explode all trees
#64 (heart NEAR/3 infarc*):ti,ab
#65 (heart NEAR/3 failure):ti,ab,kw
#66 cardiac*:ti,ab
#67 CABG:ti,ab
#68 MeSH descriptor Coronary Artery Bypass explode all trees
#69 (heart NEAR/3 bypass):ti,ab,kw
#70 (#47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60)
#71 (#61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69)
#72 (#70 OR #71)
#73 (cardiovascular NEAR/3 (outcome* or morbidity or event*)):ti,ab,kw
#74 (hospital* or admission*):ti,ab
#75 (#73 OR #74)
#76 (#8 OR #11 OR #26 OR #46 OR #72 OR #75)
#77 MeSH descriptor Sodium, Dietary explode all trees
#78 MeSH descriptor Diet, Sodium-Restricted explode all trees
#79 MeSH descriptor Sodium, this term only
#80 MeSH descriptor Sodium Chloride explode all trees
#81 (#79 OR #80)
#82 (restrict* or low* or reduc* or intak* or added or diet):ti,ab
#83 (consum* or excess* or increas* or high*):ti,ab
#84 (#82 OR #83)
#85 (#84 AND #81)
#86 (urin* or excret*):ti,ab
#87 (#80 AND #86)
#88 (restrict* NEAR/3 (salt or sodium)):ti,ab,kw
#89 (low* NEAR/3 (salt or sodium)):ti,ab,kw
#90 (reduc* NEAR/3 (salt or sodium)):ti,ab,kw
#91 (intak* NEAR/3 (salt or sodium)):ti,ab,kw
#92 (change NEAR/3 (salt or sodium)):ti,ab,kw
#93 (consum* NEAR/3 (salt or sodium)):ti,ab,kw
#94 (excess* NEAR/3 (salt or sodium)):ti,ab,kw
#95 (sodium NEAR/3 (urin* or excret*)):ti,ab,kw
#96 (increas* NEAR/3 (salt or sodium)):ti,ab,kw
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#97 (high* NEAR/3 (salt or sodium)):ti,ab,kw
#98 (added NEAR/3 (salt or sodium or food)):ti,ab,kw
#99 (diet* and (salt or sodium)):ti,ab,kw
#100 (#77 OR #78 OR #85 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 OR #
98 OR #99)
#101 (#76 AND #100)
Ovid MEDLINE(R) 1950 to October Week 4 2008
Search Date: 29 October 2008
1 Randomized controlled trial.pt.
2 randomized controlled trial/
3 (random$ or placebo$).ti,ab,sh.
4 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).tw,sh.
5 or/1-4
6 “controlled clinical trial”.pt.
7 (retraction of publication or retracted publication).pt.
8 6 or 7 or 5
9 exp Sodium, Dietary/
10 exp Diet, Sodium-Restricted/
11 Sodium/
12 Sodium Chloride/
13 11 or 12
14 (restrict* or low* or reduc* or intak* or added).tw. or diet*.mp.
15 (consum* or excess* or increas* or high*).tw.
16 14 or 15
17 13 and 16
18 (urin* or excret*).tw.
19 12 and 18
20 (restrict* adj3 (salt or sodium)).mp.
21 (low* adj3 (salt or sodium)).mp.
22 (reduc* adj3 (salt or sodium)).mp.
23 (intak* adj3 (salt or sodium)).mp.
24 (change adj3 (salt or sodium)).mp.
25 (consum* adj3 (salt or sodium)).mp.
26 (excess* adj3 (salt or sodium)).mp.
27 (sodium adj3 (urin* or excret*)).mp.
28 (increas* adj3 (salt or sodium)).mp.
29 (high* adj3 (salt or sodium)).mp.
30 (added adj3 (salt or sodium or food)).mp.
31 (diet* and (salt or sodium)).tw.
32 9 or 10 or 17 or 19 or (or/20-31)
33 exp Heart Arrest/
34 (cardiac adj3 arrest*).mp.
35 (heart adj3 arrest*).mp.
36 (cardiopulmonary adj3 arrest*).mp.
37 (sudden adj3 death).mp.
38 asystole*.mp.
39 (myocard* adj2 contract*).mp.
40 or/33-39
41 (death* or died or dead or fatal*4).ti,ab.
42 mortality.ti,ab.
43 41 or 42
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44 exp Cerebrovascular Disorders/
45 (stroke* or poststroke* or cva*).tw.
46 (cerebrovascular* or (cerebral adj vascular)).tw.
47 (cerebral or cerebellar or brain* or vertebrobasilar).tw.
48 (infarct* or isch?emi* or thrombo* or emboli* or apoplexy).tw.
49 (cerebral or intracerebral or intracranial or brain$ or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid).tw.
50 (haemorrhage or hemorrhage or bleed$ or haematoma or hematoma or aneurysm).tw.
51 48 and 47
52 49 and 50
53 trans* isch?emic attack*.tw.
54 brain attack.tw.
55 hemiplegia/
56 (hemipleg* or hemipar* or post-stroke).tw.
57 54 or 55 or 56 or 53
58 51 or 44 or 52 or 46 or 57 or 45
59 Intermittent Claudication/
60 claudica*.ti,ab.
61 exp Peripheral Vascular Diseases/
62 Vascular Diseases/
63 (peripher* adj3 (occlu* or arteri* or vascular)).ti,ab.
64 (arterial adj3 (obstruct* or occlus*)).ti,ab.
65 Arteriosclerosis Obliterans/
66 Atherosclerosis/
67 ARTERIAL OCCLUSIVE DISEASES/
68 ((leg or limb) adj3 (isch?emia or occlusi*)).ti,ab.
69 (arteriosclerosis or atherosclerosis).ti,ab.
70 Femoral Artery/
71 POPLITEAL ARTERY/
72 ILIAC ARTERY/
73 ((femoral or renal or iliac) adj3 artery).ti,ab.
74 (occlu* or obstruct*).ti,ab.
75 73 or 72 or 71 or 70
76 75 and 74
77 or/59-69
78 76 or 77
79 40 or 43 or 58 or 78
80 exp Heart Failure/
81 exp Myocardial Ischemia/
82 angina.tw.
83 angor pectoris.tw.
84 myocard*.tw.
85 Ventricular Dysfunction/
86 (ventricular adj2 failure).tw.
87 revascular*.ti,ab.
88 (isch?mi* adj3 heart).ti,ab,sh.
89 coronary.ti,ab,sh.
90 exp Angioplasty/
91 Angioplasty, Transluminal, Percutaneous Coronary/
92 (PTCA or angioplast*).tw.
93 Myocardial Revascularization/
94 stenocardia*.tw.
95 (heart adj3 decompensation).tw.
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96 exp Myocardial Infarction/
97 (heart adj3 infarc*).tw.
98 (heart adj3 failure).ti,ab,sh.
99 cardiac*.tw.
100 CABG.tw.
101 exp coronary artery bypass/
102 (heart adj3 bypass).tw,sh.
103 or/80-102
104 (cardiovascular adj3 (outcome* or morbidity or event*)).mp. [mp=title, original title, abstract, name of substance word, subject
heading word]
105 (hospital* or admission*).tw.
106 104 or 105
107 103 or 106 or 58 or 78 or 43 or 40
108 32 and 107
109 (animals not humans).sh.
110 exp Case Reports/
111 letter.pt.
112 (news or editorial).pt.
113 111 or 110 or 112
114 108 not 113
115 114 not 109
116 8 and 115
EMBASE OVID SP <1980 to 2008 Week 43>
Search Date: 30 October 2008
1 sodium intake/
2 sodium restriction/
3 Sodium/
4 Sodium Chloride/
5 3 or 4
6 (restrict* or low* or reduc* or intak* or added).tw. or diet*.mp.
7 (consum* or excess* or increas* or high*).tw.
8 6 or 7
9 5 and 8
10 (urin* or excret*).tw.
11 4 and 10
12 (restrict* adj3 (salt or sodium)).mp.
13 (low* adj3 (salt or sodium)).mp.
14 (reduc* adj3 (salt or sodium)).mp.
15 (intak* adj3 (salt or sodium)).mp.
16 (change adj3 (salt or sodium)).mp.
17 (consum* adj3 (salt or sodium)).mp.
18 (excess* adj3 (salt or sodium)).mp.
19 (sodium adj3 (urin* or excret*)).mp.
20 (increas* adj3 (salt or sodium)).mp.
21 (high* adj3 (salt or sodium)).mp.
22 (added adj3 (salt or sodium or food)).mp.
23 (diet* and (salt or sodium)).tw.
24 1 or 2 or 9 or 11 or (or/12-23)
25 exp Heart Arrest/
26 (cardiac adj3 arrest*).mp.
27 (heart adj3 arrest*).mp.
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28 (cardiopulmonary adj3 arrest*).mp.
29 (sudden adj3 death).mp.
30 asystole*.mp.
31 (myocard* adj2 contract*).mp.
32 or/25-31
33 (death* or died or dead or fatal*4).ti,ab.
34 mortality.ti,ab.
35 33 or 34
36 exp Cerebrovascular Disease/
37 (stroke* or poststroke* or cva*).tw.
38 (cerebrovascular* or (cerebral adj vascular)).tw.
39 (cerebral or cerebellar or brain* or vertebrobasilar).tw.
40 (infarct* or isch?emi* or thrombo* or emboli* or apoplexy).tw.
41 (cerebral or intracerebral or intracranial or brain$ or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid).tw.
42 (haemorrhage or hemorrhage or bleed$ or haematoma or hematoma or aneurysm).tw.
43 40 and 39
44 41 and 42
45 trans* isch?emic attack*.tw.
46 brain attack.tw.
47 hemiplegia/
48 (hemipleg* or hemipar* or post-stroke).tw.
49 46 or 47 or 48 or 45
50 43 or 36 or 44 or 38 or 49 or 37
51 Intermittent Claudication/
52 claudica*.ti,ab.
53 exp Peripheral Vascular Disease/
54 Vascular Disease/
55 (peripher* adj3 (occlu* or arteri* or vascular)).ti,ab.
56 (arterial adj3 (obstruct* or occlus*)).ti,ab.
57 Arteriosclerosis Obliterans/
58 Atherosclerosis/
59 Peripheral Occlusive Artery Disease/
60 ((leg or limb) adj3 (isch?emia or occlusi*)).ti,ab.
61 (arteriosclerosis or atherosclerosis).ti,ab.
62 Femoral Artery/
63 POPLITEAL ARTERY/
64 ILIAC ARTERY/
65 ((femoral or renal or iliac) adj3 artery).ti,ab.
66 (occlu* or obstruct*).ti,ab.
67 65 or 64 or 63 or 62
68 67 and 66
69 or/51-61
70 68 or 69
71 exp Heart Failure/
72 exp Heart Muscle Ischemia/
73 angina.tw.
74 angor pectoris.tw.
75 myocard*.tw.
76 Heart Ventricle Function/
77 (ventricular adj2 failure).tw.
78 revascular*.ti,ab.
79 (isch?mi* adj3 heart).ti,ab,sh.
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80 coronary.ti,ab,sh.
81 exp Angioplasty/
82 exp Transluminal Coronary Angioplasty/
83 (PTCA or angioplast*).tw.
84 exp Heart Muscle Revascularization/
85 stenocardia*.tw.
86 (heart adj3 decompensation).tw.
87 exp Heart Infarction/
88 (heart adj3 infarc*).tw.
89 (heart adj3 failure).ti,ab,sh.
90 cardiac*.tw.
91 CABG.tw.
92 exp Coronary Artery Bypass Graft/
93 (heart adj3 bypass).tw,sh.
94 or/71-93
95 (cardiovascular adj3 (outcome* or morbidity or event*)).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name]
96 (hospital* or admission*).tw.
97 95 or 96
98 94 or 97 or 50 or 70 or 35 or 32
99 24 and 98
100 ((animal$ or Nonhuman$) not human$).sh,hw.
101 letter.pt.
102 editorial.pt.
103 102 or 101 or 100
104 99 not 103
105 Randomized Controlled Trial/
106 Single Blind Procedure/
107 Double Blind Procedure/
108 Crossover Procedure/
109 105 or 106 or 107 or 108
110 (random$ or factorial$ or crossover$ or placebo$ or (cross adj over) or assign$).ti,ab.
111 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).ti,ab.
112 controlled clinical trial*.ti,ab.
113 112 or 110 or 111 or 109
114 104 and 113
PsycINFO (OVID) 1806 to October Week 4 2008
Search Date:
1 (random$ or placebo$ or rct).tw,sh.
2 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).tw,sh.
3 (“2000” or treatment outcome clinical trial).md.
4 ((retract$ or withdraw$) adj (public$ or article$)).tw.
5 or/1-4
6 Sodium/
7 (diet and (salt or sodium)).mp.
8 (restrict* adj3 (salt or sodium)).mp.
9 (low* adj3 (salt or sodium)).mp.
10 (reduc* adj3 (salt or sodium)).mp.
11 (intak* adj3 (salt or sodium)).mp.
12 (change adj3 (salt or sodium)).mp.
13 (consum* adj3 (salt or sodium)).mp.
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14 (excess* adj3 (salt or sodium)).mp.
15 (sodium adj3 (urin* or excret*)).mp.
16 (increas* adj3 (salt or sodium)).mp.
17 (high* adj3 (salt or sodium)).mp.
18 (added adj3 (salt or sodium or food)).mp.
19 or/6-18
20 exp Heart Arrest/
21 exp heart disorders/
22 (cardiac adj3 arrest*).mp.
23 (heart adj3 arrest*).mp.
24 (cardiopulmonary adj3 arrest*).mp.
25 (sudden adj3 death).mp.
26 asystole*.mp.
27 (myocard* adj2 contract*).mp.
28 or/20-27
29 (death* or died or dead or fatal*4).ti,ab.
30 mortality.ti,ab.
31 29 or 30
32 exp Cerebrovascular Disorders/
33 (stroke* or poststroke* or cva*).tw.
34 (cerebrovascular* or (cerebral adj vascular)).tw.
35 (cerebral or cerebellar or brain* or vertebrobasilar).tw.
36 (infarct* or isch?emi* or thrombo* or emboli* or apoplexy).tw.
37 (cerebral or intracerebral or intracranial or brain$ or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid).tw.
38 (haemorrhage or hemorrhage or bleed$ or haematoma or hematoma or aneurysm).tw.
39 36 and 35
40 37 and 38
41 32 or 33 or 34 or 39 or 40
42 trans* isch?emic attack*.tw.
43 brain attack.tw.
44 hemiplegia/
45 (hemipleg* or hemipar* or post-stroke).tw.
46 43 or 44 or 45 or 42
47 claudica*.ti,ab.
48 (peripher* adj3 (occlu* or arteri* or vascular)).ti,ab.
49 (arterial adj3 (obstruct* or occlus*)).ti,ab.
50 Atherosclerosis/
51 ((leg or limb) adj3 (isch?emia or occlusi*)).ti,ab.
52 (arteriosclerosis or atherosclerosis).ti,ab.
53 ((femoral or renal or iliac) adj3 artery).ti,ab.
54 (occlu* or obstruct*).ti,ab.
55 or/47-54
56 Heart Failure.mp.
57 ischemia/ and myocard$.tw.
58 angina.tw.
59 angor pectoris.tw.
60 myocard*.tw.
61 Ventricular Dysfunction/
62 (ventricular adj2 failure).tw.
63 revascular*.ti,ab.
64 (isch?mi* adj3 heart).ti,ab,sh.
65 coronary.ti,ab,sh.
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66 heart surgery/
67 (PTCA or angioplast*).tw.
68 stenocardia*.tw.
69 (heart adj3 decompensation).tw.
70 exp Myocardial Infarction/
71 (heart adj3 infarc*).tw.
72 (heart adj3 failure).ti,ab,sh.
73 cardiac*.tw.
74 CABG.tw.
75 (heart adj3 bypass).tw,sh.
76 or/56-75
77 (cardiovascular adj3 (outcome* or morbidity or event*)).mp. [mp=title, abstract, heading word, table of contents, key concepts]
78 (hospital* or admission*).tw.
79 77 or 78
80 editorial.dt.
81 letter.dt.
82 80 or 81
83 28 or 31 or 41 or 46 or 55 or 76 or 79
84 83 and 19
85 84 and 5
86 85 not 82
87 86
88 limit 87 to human
CINAHL
WEB 2.0
Search Date: 03 November 2008
1 SODIUM CHLORIDE, DIETARY/ OR DIET, SODIUM-RESTRICTED/
2 SODIUM/
3 SODIUM CHLORIDE/
4 ((restrict* OR low* OR reduc* OR intak* OR added) OR diet*).ti,ab
5 ((consum* OR excess* OR increas* OR high*)).ti,ab
6 4 OR 5
7 6 AND (2 or 3)
8 ((urin* OR excret*)).ti,ab
9 3 AND 8
12 ((restrict* AND (salt OR sodium))).ti,ab
13 ((low* AND (salt OR sodium))).ti,ab
14 ((reduc* AND (salt OR sodium))).ti,ab
15 ((intak* AND (salt OR sodium))).ti,ab
16 ((change AND (salt OR sodium))).ti,ab
17 ((consum* AND (salt OR sodium))).ti,ab
18 ((excess* AND (salt OR sodium))).ti,ab
19 ((sodium AND (urin* OR excret*))).ti,ab
20 ((increas* AND (salt OR sodium))).ti,ab
21 ((high* AND (salt OR sodium))).ti,ab
22 ((added AND (salt OR sodium OR food))).ti,ab
23 ((diet* AND (salt OR sodium))).ti,ab
24 1 OR 7 OR 9 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23
25 24 [Limit to: (Publication Type Clinical Trial or Systematic Review)]
26 ((placebo* OR random* OR rct)).ti,ab
27 (((singl* OR double* OR triple* OR treble*) AND (blind* OR mask*))).ti,ab
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28 ((controlled clinical trial)).ti,ab
29 26 OR 27 OR 28
30 24 AND 29
31 25 OR 30 [Limit to: (Publication Type Clinical Trial or Systematic Review)]
H I S T O R Y
Review first published: Issue 7, 2011
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
- Given the small number of trials included in this review it was not possible to undertake exploration of heterogeneity using stratified
meta-analysis or meta-regression
- Studies reporting death or cardiovascular outcomes were included regardless of the number of events in intervention and controls.
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